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 ABSTRACT 
Background: Breast carcinoma (BC) is the most common form of malignancy in women 
and the leading cause of cancer-related mortality among females internationally. BC 
includes a series of heterogeneous tumours with a great variability at histological level, 
biological level and clinical evolution. Because its complexity, BC treatment 
recommendations are continually changing with the new advances in this field. However 
there are still a significant number of patients with similar features that show distinct 
outcome. In order to detect the existing molecular differences and address patients to more 
personalized treatment, there is a need to find out new cancer biomarkers. 
Aim: The main goal of my PhD project is to investigate on the possibility of combining 
traditional clinical and pathological features with new candidate biomarkers for the 
prognostication of breast cancer. The first part concerns the prognostic role of molecular 
classification of primary tumours, according to luminal A, luminal B, HER-2+ and basal-
like subtypes. In the second part, the prognostic value of nine candidate genes was 
investigated at mRNA level. The genes of interest belong to the RB pathway (RB and 
CDK2), the RAS pathway (HER-2, PI3K, AKT1, AKT2, AKT3 and RAF1), and cellular 
differentiation mechanism (CK8), all involved in major cancer hallmarks, such as cell 
proliferation and survival. 
Methods: This retrospective study comprises 305 women, which presented stage I-III 
invasive BC, age at diagnosis ≤55 years, and long follow-up period if alive. The cohort 
includes 151 lymph node negative (LN-) and 154 lymph node positive (LN+) patients. The 
molecular classification of primary tumours was performed by means of 
immunohistochemistry (IHC), using seven surrogate markers: ER, PR, HER-2, Ki67, CK8 
and CK5/6, plus vimentin. Results of molecular classification were analysed with respect to 
morphologic and pathological features, and outcome. Moreover, the molecular 
characterization was also performed in a set of loco-regional metastatic lymph nodes, to 
compare the phenotype of primary tumour cells with their matched metastatic cells 
colonizing regional nodes. To the second purpose, gene’s expression was investigated in the 
entire cohort of primary tumours by means of real-time PCR, using the TaqMan chemistry. 
The expression of the nine genes was investigated in connection with the clinical-
pathological factors, molecular classification and BC specific patient’s survival.
 Results: Regarding molecular classification of primary tumours, luminal A, luminal B, 
HER-2+ and basal-like accounted for 46%, 34%, 8% and 12% respectively. Luminal A 
tumours were mainly LN-, well differentiated and stage I, while luminal B and HER2+ 
showed higher tumour grade, nodal metastases as well as higher proliferation status and 
stage. Luminal A exhibited better survival in comparison to the other subtypes (p<0.001). 
HER2+ and basal-like showed a poorer outcome, with a BC specific death occurring mostly 
within 5 and 10 years, respectively. Despite of the longer survival of patients with luminal 
tumours, they are the only one that underwent long-term recurrences, especially those 
patients characterized by high mitotic index and positive vimentin. The molecular 
classification at the level of loco-regional metastasis, revealed that HER-2, Ki67, CK8 and 
vimentin positivity was significantly decreased, whereas CK5/6 positivity was increased. 
No significant differences for ER and PR positivity between primary and metastatic lesions 
were found. The assessment of CK8 expression in the metastatic nodes was significantly 
associated to BC specific survival. Regarding gene’s expression, we found a significant 
higher expression of RB, PI3K, AKT2 and AKT3 in LN- group, while CDK2, HER-2, 
AKT1 and CK8 were higher expressed in LN+ group. CDK2 high expression was 
significantly associated to the presence of later recurrences, in the entire cohort of patients. 
We also found specific pattern of genes’ expression among molecular classes for: CDK2, 
HER-2, PI3K, AKT2, AKT3 and CK8. Survival analysis revealed that: i) high status of 
AKT1 and AKT2 seem to be related to worse survival in the entire cohort; ii) AKT3 and RB 
were associated to longer survival in LN-; iii) high AKT2 expression in luminal B seem to 
be associated to shorter survival; iv) high AKT3 status was associated to longer survival in 
luminal A tumours.  
Conclusions: We believe that the use of the traditional biomarkers ER, PR, HER-2 and 
Ki67 is essential for BC characterisation and prognostication in association with clinical 
pathological features. Nevertheless, we identified new molecular markers that could better 
distribute patients into more homogeneous subgroups of BC. Finally, high AKT3 expression 
at mRNA level seems to be an independent indicator of good prognosis in patients showing 
ER+/HER2- and low proliferation index tumours. 
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1 INTRODUCTION 
Cancer represents a major public health problem in western societies, for this reason in the 
last decades many efforts aimed to defeat cancer have been made.  
Standard diagnostic procedures for human tumours are worldwide performed in formalin 
fixed and paraffin embedded (FFPE) tissues, through histopathological examination and 
immunohistochemistry analysis combined to clinical data. The histopathological approach is 
aimed to define the nature, the tissue origin, the morphologic characteristics and the 
evolution of the disease (Comanescu et al., 2012). More recently, immunohistochemistry 
analysis allowed pathologists to complement morphology information to reach a better 
classification of tumours (Comanescu et al., 2012). Those data are relevant also for patient’s 
prognosis and represent the rational basis for the choice of therapy. However, cancer is a 
heterogeneous and complex disease with differences also at the molecular level. Patients, 
with the same histopathological features could have very different clinical outcome. To 
improve this situation during recent years many efforts have been made to find molecular 
markers and gene signatures useful to predict patients’ prognosis. All the experiments 
performed in this research were carried out on formalin fixed and paraffin embedded 
(FFPE) tissues, since they are greatly available and they could be selected with long follow-
up period. Recently, most molecular analyses can be made in FFPE tissues (Stanta, 2011), 
consequently it is possible to gain new knowledge on cancer directly on human tissues, with 
a substantial reduction of the time needed for clinical application, compared to basic 
research. 
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1.1 Epidemiology 
1.1.1 Breast Cancer Incidence and Mortality 
Invasive breast cancer is the most common cancer among women. In 2008 a total of 1.38 
million of breast cancer cases were diagnosed worldwide, accounting for 23% of all 
invasive cancer in female that year (Ferlay et al., 2010). To date, it is the most frequent 
cancer both in more developed and developing countries with an estimation of 690,000 new 
cases/year, but the rates of incidence are quite different after population size and age 
standardization: 71.7/100,000 for developed regions, and 29.3/100,000 for developing 
countries (Youlden et al., 2012). The incidence increases with age and the 89% of women 
with breast cancer are over 40 years (Ferlay et al., 2010). Highest incidence rates were 
recorded in Western Europe, Australia, Northern Europe and Northern America, where 
almost a 6% of women develop BC before 75 years age (Ellis et al., 2003) .Contrarily, the 
lowest incidence rates were observed in Eastern Africa, Middle Africa and Melanesia (Fig 
1). Japan is the only developed country which showed a low incidence rate (Ellis et al., 
2003). The discrepancy in incidence rates over the above-mentioned countries, is mainly 
due to social-cultural factors and lifestyle.  
In the last decades, the achievement of an increasing quality of diagnostic and therapeutic 
technologies improved significantly the outcome of women with breast cancer in more 
developed countries.  
 
Although the incidence of breast cancer is slightly increased, there is a significant 
decrement in the mortality rate, with an overall rate of mortality of 6-19/100,000. Almost 
459,000 dead women for breast cancer were estimated worldwide in 2008 (Youlden et al., 
2012). However breast cancer is the leading cause of cancer related mortality in women, 
representing almost 14% of all cancer deaths (Youlden et al., 2012). Although more breast 
cancer deaths occurred in less developed countries, the mortality rate was generally higher 
in developed countries (11.8 and 17.1 deaths per 100,000, respectively), as reported in 
Fig.1. Data from Italian register of tumours ranked BC first with an occurrence of 17% of 
all cancers death among females in the period 1998-2002 (http://www.registri-
tumori.it/cms/?q=sede_mammella). 
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The rate of survival for women with breast cancer is higher than for other tumours, currently 
it is expected that about 20% of women with this disease die of it (Lester, 2010). In 
developed countries the five-year relative survival tended to be higher, between 95% and 
90%, in North America, Australia, Japan and Northern Europe; while is lower in Eastern 
Europe and United Kingdom, between 75% and 80%. Limited data are available for Asia, 
Africa and South America (Youlden et al., 2012). In Italy, in 2007 was estimated a 5-year 
relative survival of 85% (84-85%) in all women (http://www.registri-
tumori.it/cms/?q=sede_mammella). 
 
Fig. 1. Estimated age-standardized rates world (per 100,000) of BC incidence and mortality in female. 
Data from Globocan 2008. 
 
1.1.2  Aetiology 
Breast cancer is a multifactorial disease being related both to environmental and genetic 
factors. Epidemiological studies have shown that breast cancer is a disease of the affluent 
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societies (Ellis et al., 2003), which are characterized by the acquisition of the Western 
countries’ lifestyle (Porter, 2008). Consequently, environmental and lifestyle factors are 
important risk factors. Studies on Asian migrants to United States showed an increased 
incidence rate across successive generations (Richie and Swanson, 2003). Women in 
developed country acquire risk factors, such as having few children or having them at older 
age, following high-caloric diet with meat and saturated animal fat and excessive 
consumption of alcohol (Youlden et al., 2012). Also a lower level of physical activity may 
contribute to increase the risk. 
Gender represents the main discriminant factors, breast cancer occurs 100 times more 
frequently in women respect to men (Richie and Swanson, 2003), because in men the breast 
is a vestigial organ less sensitive to the hormones’ action.  
As for many other diseases, the higher risk factor is the aging process (Ferlay et al., 2010). 
BC is rare under 25 years, with an increasing incidence up to 50-60 years, then, there is a 
plateau and a recovery after 65 years. The likelihood of developing breast cancer is 0.4% in 
women younger than 39 years, 3.86% in women of age 40-59 years, 3.51% for the interval 
60-69 years and 6.95% for women with an age of 70 or older (Vetto et al., 2009). This 
phenomenon probably reflect the menopause status and the changes in hormone cycle 
(Richie and Swanson, 2003).  
Hormonal history is a significant risk factor. Early menarche (age less than 13 years), 
having no or few children, having an older age at first childbearing, lack of breast-feeding, 
menopause after age of 50 are all events considered to increase the risk of breast carcinoma 
since they lead to a greater exposure to hormones. Consequently in developed countries a 
decreasing rate of incidence among women aged 50-69 years in the last decade in parallel to 
the declining use of hormone replacement therapy has been observed (HRT) (Kumle, 2008; 
Richie and Swanson, 2003). Oestrogen and progestin together increase the risk more than 
oestrogen alone. A randomized controlled trial on postmenopausal women ‘Womens’ 
Health Initiative’ (Rossouw et al., 2002) showed that the use of HRT increased the risk of 
develop a breast cancer of 53% for combination therapy, and 34% of increased risk for 
oestrogen alone, when HRT were administered for more than five years (Rossouw et al., 
2002).  
Approximately 10% to 15% of cases have a familial predisposition, while only a 5% of 
breast cancers are caused by hereditary syndrome (van der Groep et al., 2011), about 25% of 
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those cases can be referred to genetic mutation in two autosomal dominant genes: BRCA1 
and BRCA2, which are tumour suppressor genes (Venkitaraman, 2002). Women with a 
first-degree relative (mother, sister, daughter) with breast cancer presented 2-fold higher 
risk of developing a carcinoma. There is a 5-fold increase risk for women with two first-
degree relatives with breast cancer (Richie and Swanson, 2003).  
Other risk factors include diet, as consumption of alcohol and obesity, since fat tissue 
produces hormones, which are converted to oestrogen.  
Ionizing radiation exposure is another risk factor. The risk is increased in younger age and 
with increasing doses of radiation (Lester, 2010).  
The last risk factor is represented by breast cancer itself: a percentage of 10% of patients 
with previous BC develop a second breast cancer, and the risk of developing a carcinoma in 
the contralateral breast is 3 to 7 times higher (Richie and Swanson, 2003). 
 
1.2 Histological Classification 
Most breast tumours are carcinomas, about 5% are squamous carcinomas, sarcomas, 
lymphomas and phyllodes tumours (Lester, 2010). Carcinomas are divided into in situ and 
invasive carcinomas. For in situ carcinoma the proliferation of neoplastic cells is confined to 
the ducts and lobules of the basal membrane. This type does not infiltrate the lymph 
vascular veins consequently it cannot metastasize. Conversely, invasive carcinoma has 
already exceeded the basal membrane invading the stroma, and the neoplastic cells can 
spread both to the regional or distant lymph nodes, or others sites. 
In 1973 Wellings and Jensen were first to demonstrate that the vast majority of breast 
carcinoma originates from the epithelial cells of the terminal ductal lobular unit (TDLU), 
independently from histological type (Wellings and Jensen, 1973). Even if it is still common 
to describe the in situ and the infiltrating types as ductal or lobular, due to their similarity to 
ducts and lobules, the terms ductal and lobular do not indicate the site of origin of the 
carcinoma.  
There are some differences in the localization sites of BC. The frequency of carcinoma in 
the left breast is slightly higher than the right, with a ratio of 1.07 to 1. Moreover, almost the 
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50% of tumours occur in the upper outer quadrant of the breast, while the lower inner 
quadrant is the less frequent localization site (Ellis et al., 2003). 
 
Fig. 2. Representation of the terminal ductal lobular unit (TDLU) of the breast. Taken from Davidson, 
T (Davidson, 2001). 
 
The histological classification reported here is based on the 2nd edition WHO classification 
of malignant primary tumour of the breast (Ellis et al., 2003). The WHO classification 
recognizes 17 special histological types of BC, which represent the 25% of all invasive 
cancers (Ellis et al., 2003; Rakha and Ellis, 2011).  
The in situ carcinoma is histologically classified as ductal (DCIS), which represent the 15-
30% of all BC, and lobular (CLIS), with 1-6% of breast tumours.  
There are several histological types for invasive BC. The invasive ductal carcinoma (IDC), 
not otherwise specified (NOS), is the commonest (40-75%) and comprises a heterogeneous 
group of tumours that cannot be classified as others specific histological type, so their 
morphological features are mixed. The invasive lobular carcinoma (ILC) represents 5-15% 
of invasive breast tumours. The incidence of ILC is reported to increase in postmenopausal 
women in the last two decades, which may be due to the use of hormone replacement 
therapy (HRT) (Ellis et al., 2003). At macroscopic analysis, ILC tumours show irregular and 
poorly delimited margins, which can be hardly to define because of the diffuse growth 
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pattern of cell infiltrate. Tumour cells appear individually dispersed through connective 
tissues, or they can appear arranged in single linear rows. This morphologic pattern was 
correlated with the lack of E-cadherin, responsible for cellular cohesion. The regional lymph 
node involvement is less frequent in ILC than IDC. Another histological type is the tubular 
carcinoma, which is characterized by a good prognosis. Unfortunately, this type accounts 
for only 2% of breast cancers. Its histopathological hallmarks are the presence of well-
differentiated tubular structures with open lumina, surrounded by a single layer of epithelial 
cells. Conversely, medullary carcinoma, which accounts for 1-7% of all BC, is composed by 
poorly differentiated cells immersed in a few stroma, without glandular structures and high 
lymphocytic infiltrate. This type is frequently observed in hereditary tumours characterized 
by BRCA1 mutation. The mucin producing carcinomas comprise a variety of tumours. 
Mucinous carcinoma (also called colloid), for instance, is characterized by little group of 
small and uniform cells immersed in large amount of extracellular mucus. It accounts for 
2% of all breast carcinomas and, generally, it shows a favourable prognosis. The 
neuroendocrine carcinoma accounts for 2-5% of breast carcinomas and they are 
characterised by the expression of neuroendocrine markers such as chromogranin and 
synaptophysin proteins in more than 50% of tumour cells. Less frequent histological types 
include invasive papillary carcinoma (1-2%), invasive cribriform carcinoma (∼1%), 
apocrine carcinoma (∼1%) and metaplastic carcinoma (<1%) (Ellis et al., 2003). 
 
1.2.1  Relation of Benign Breast Lesions with Breast Carcinoma 
Several epidemiological studies analysed the benign lesions and investigated on the risk of 
these lesion to evolve to BC (Beckmann et al., 1997; Richie and Swanson, 2003; Schnitt, 
2003). Non proliferative-lesions as fibrosis or cysts do not increase the risk of breast 
carcinoma (Richie and Swanson, 2003). Otherwise, proliferative-lesions such as hyperplasia 
and papilloma are associated to a slight increase of risk. Proliferative lesions with atypia as 
Atypical Ductal Hyperplasia (ADH) and Atypical Lobular Hyperplasia (ALH) give a 
moderate increase in the risk of developing a carcinoma (Beckmann et al., 1997; Lester, 
2010). The in situ carcinoma, if not treated, confers a high risk of developing an invasive 
one. (Schnitt, 2003). Women with a history of CLIS, ADH, ALH and atypical papilloma 
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show three to five times greater risk of breast cancer. Also the genetic mutations in BRCA1 
or BRCA2 genes confer a risk of 60-80% of developing BC (Lester, 2010). 
 
1.3  TNM Staging 
The tumour, node, metastases system (TNM) is the most used staging classification for 
tumours. It was accepted from the International Union Against Cancer (UICC) and the 
American Joint Committee on Cancer (AJCC) and it is constantly revised and updated 
(Edge et al., 2010a). 
The TNM system was designed to reflect the risk of distant recurrences and death after the 
local therapy, which was radical mastectomy and postoperative radiation. Consequently, the 
TNM staging for BC tries to supply a standard nomenclature to define the prognosis of BC 
patients, and also provide a clinical tool for the treatment decision (Edge et al., 2010a) 
(http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-staging).  
There is clinical (c) and pathologic staging (p) for tumour, node and metastases sites. The 
clinical staging is based on information obtained before surgery or neo-adjuvant therapy; 
while the pathologic staging refers to information defined during surgery. In the following 
table the pTNM classification according to the 7TH edition of AJCC is reported (Edge et al., 
2010a).  
Primary Tumour (T) Ragional Lymph nodes (N) Distant Metastasis (M) 
TX Cannot be assesed NX Cannot be assessed M0 
No evidence of 
distant 
metastases 
T0 
No evidence of primary 
tumour 
N0 
No regional lymph 
nodes metastases 
cM0(i+) 
No evidence of 
distant 
metastases, but 
small number of 
cancer cells in 
circulating 
blood, bone 
marrow that are 
no larger than 
0.2 mm 
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Tis 
Carcinoma in situ (DCIS, 
LCIS, Paget’s disease) 
N1 
(includes 
Nimi, 
N1a, N1b, 
N1c) 
Cancer has spread to 1 
to 3 axillary lymph 
node(s), and/or tiny 
amounts of cancer are 
found in internal 
mammary lymph nodes 
on sentinel lymph node 
biopsy 
M1 
Distant 
detectable 
metastases 
larger than 0.2 
mm 
T1 
(includes 
T1a, T1b, 
T1c) 
Tumour ≤20 mm in 
greatest dimension 
N2 
(includes 
N2a, N2b) 
Cancer has spread to 4 
to 9 lymph nodes under 
the arm, or cancer has 
enlarged the internal 
mammary lymph nodes 
  
T2 
Tumour ≥20 mm but ≤50 
mm in greatest dimension 
N3 
(includes 
N3a, N3b, 
N3c) 
Metastases in 10 or 
more axillary lymph 
nodes, or in 
infraclavicular nodes, or 
in ipsilateral 
supraclavicular nodes, 
or clinically detected 
ipsilateral internal 
mammary nodes in 
presence of axillary 
positive nodes. 
  
T3 
Tumour >50 mm in 
greatest dimension 
    
T4 
(Includes 
T4a, T4b, 
T4c, T4d) 
Tumour of any size with 
direct extension to the 
chest wall and/or skin 
    
Table 1. TNM classification according to the 7th edition of AJCC Cancer Staging Handbook (Edge et 
al., 2010a, b). the letter T followed by a number from 0 to 4 describes the tumour size and 
eventual extension to the skin or chest wall. Tis indicates the in situ carcinoma. The letter N 
followed by a number from 0 to 3 describes if the cancer has spread to lymph nodes near the 
breast, and how many of them are involved. The letter M followed by 0 or 1 indicates whether 
the cancer has spread to distant organs. 
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After the TNM have been estimated, this information is combined to define the anatomic 
stage. Non-invasive cancer is staged as 0, stage I represent the least advanced stage, while 
stage IV the most advanced (table 2). 
Stage 0 Tis N0 M0 
Stage IA T1 N0 M0 
Stage IB T0 or T1 N1mi M0 
Stage IIA 
T0 
T1 
T2 
N1 
N1 
N0 
M0 
M0 
M0 
Stage IIB 
T2 
T3 
N1 
N0 
M0 
M0 
Stage IIIA 
T0 
T1 
T2 
T3 
T3 
N2 
N2 
N2 
N1 
N2 
M0 
M0 
M0 
M0 
M0 
Stage IIIB 
T4 
T4 
T4 
N0 
N1 
N2 
M0 
M0 
M0 
Stage IIIC Any T N3 M1 
Stage IV Any T Any N M1 
Table 2. BC stages according to the 7th edition of AJCC Cancer Staging Handbook (Edge et al., 2010a) 
 
1.4  Histological Grading 
Histological grade is mainly used for invasive carcinomas and it provides important 
prognostic information. It refers to the cytological features of cancer cells in comparison to 
the normal ones. The grade is assessed through the analysis of three morphological features: 
the tubule formation, the nuclear pleomorphism and the mitotic count. Tubular formation 
has cut-off points of 75% and 10% (Ellis et al., 2003; Elston and Ellis, 1991). Nuclear 
pleomorphism is assessed through the nuclear size and shape of cancer cells in comparison 
to normal epithelia cells in adjacent breast tissue. For the identification of mitotic figures 
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only nuclei in clear morphologic features of metaphase, anaphase and telophase are counted. 
For each of these aspects, a score from 1 to 3 is given. Then, the total score is obtained 
adding single values (3-9) and the histological grading is defined as follow (Elston and 
Ellis, 1991): 
• 3-5 points: well differentiated tumour, namely Grade 1 (G1); 
•  6-7 points: moderately differentiated tumour, Grade 2 (G2);  
• 8-9 points: poorly differentiated tumour, Grade 3 (G3); 
Currently, histological grading is performed using the “Nottingham Grade” (Elston and 
Ellis, 1991). Although the clinical significance of grade 1 and 3 is well established, 
approximately 50% of tumours are classified as grade 2, which has equivocal clinical 
significance (Weigelt et al., 2010a). Histological grade has been included in validated 
prognostic algorithms to define BC therapy, as Nottingham prognostic index and Adjuvant 
Online! (Galea et al., 1992; Mook et al., 2009). The combination of histological grade and 
type provide complementary information (Rakha et al., 2008a) and a more accurate 
assessment of prognosis. 
 
1.5  Mechanism of Carcinogenesis 
Tumourigenesis in humans is a multistep process, in which the steps reflect the genetic 
alterations that lead the progressive transformation of normal cells to malignant ones. 
According to the general model of tumourigenesis of Hanahan and Weinberg, normal cells 
must acquire six news properties for becoming malignant (Hanahan and Weinberg, 2000). 
The abovementioned events are:  
• self-sufficiency in growth signal, to provide mitogenic stimulatory signals of 
growth;  
• insensitivity to anti-growth signals, to move the cell into an active proliferative 
status;  
• evading apoptosis;  
• limitless replicative potential, to circumvention the process of senescence;  
• sustained angiogenesis, crucial for providing oxygen and nutrients;  
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• tissue invasion and metastases. 
The molecular mechanisms and the main molecular actors, which lead to cell 
transformation, are largely unknown in BC. The molecular heterogeneity of the tumour 
reflects the concomitant development of different foci and witnesses that malignant 
transformation is the result of sequential multistep evolution (Beckmann et al., 1997). The 
development of BC is the result of a complex interaction between genetic predisposing 
factors, somatic mutations and hormones, which are playing a major role in several stages of 
the neoplastic transformation. BRCA1, for instance, is controlled by oestrogen and 
progesterone receptors. Hereditary carcinomas originate from cells with germline mutations, 
which alter DNA repair and normal apoptosis signals. Consequently, those cells need lower 
number of acquired mutations to transform into malignant ones. For example, both BRCA1 
and BRCA2 genes are involved in the maintenance of DNA integrity. BRCA genes form 
complexes that will activate the repair machinery and also, start the homolog recombination. 
In hereditary carcinomas, the mutant allele of BRCA is inherited while the other allele is 
inactivated by a sporadic mutation. In major cases, the loss of BRCA1 is due to the loss of 
heterozygosity (LOH) in association to the methylation of promoter (Lester, 2010; van der 
Groep et al., 2011).  
Concerning DNA mutations, in cancer there are two major classes of alterations: gain of 
functions or amplifications that activate the oncogenes; deletions or allelic loss that defect 
the tumour suppressor genes. Particularly in BC, the chromosomal sites which harbour 
oncogenes are marked by regions of DNA amplification, while point mutation of oncogenes 
are rare events. Beckmann et al. reported that although many oncogenes are reported to be 
involved in human cancer, only few oncogenes seem to be involved in BC development. 
These include three chromosome localizations: 8q24 (c-myc), 11q13 (int2, BCL2, EMS1, 
FGF3/4, CCND1), 17q12 (HER-2 or c-erbB2). It is important to stress that none of these 
oncogenes were found amplified in benign breast lesions. Actually, oncogenes amplification 
does not occur in the early stages of BC carcinogenesis, but it is first detected in DCIS. For 
example the overall rate of HER-2 amplification in DCIS is 33–61%, while it decrease 
towards the development of invasive ductal carcinoma (10–26%) (Beckmann et al., 1997).  
However, women with atypical hyperplasia characterised by HER-2 expression have a 
seven-fold increased risk of develop invasive BC in comparison to cases without HER-2 
amplification (Richie and Swanson, 2003). 
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The tumour suppressor TP53 appears constantly mutated in about 22-34% of sporadic BC, 
with a point mutation. Particular sites of LOH have been observed both in hereditary and 
sporadic breast cancer, but not in benign breast disease.  
The first alteration observed in benign lesions is the increasing number of epithelial cells, 
which evade signals of growth inhibition and apoptosis. It seems that abnormal expression 
of hormonal receptors occurs even in this phase. Genetic instability is referred as a later 
event, since it appears in atypical dysplasia and in situ carcinoma. Evident aneuploidy and 
angiogenesis are observed subsequently in DCIS and invasive carcinoma (Beckmann et al., 
1997).  
Other alterations can be also frequently found in primary breast carcinomas, namely 
amplification of cyclin D1 and MDM2, loss of RB function, inactivation of p16 by promoter 
hypermethylation of 5-CpG island (Beckmann et al., 1997). 
 
1.6  Prognostic and Predictive Factors in Breast Cancer  
In BC, both pathological and molecular factors are commonly used in clinical routine to 
provide prognostic and predictive information for patients. Prognostic factors are intended 
to predict in objective and independent way the patients’ clinical outcome, independently 
from systemic therapy. Predictive factors are able to predict the response to a specific 
treatment. Nevertheless, there is often an overlap between prognostic and predictive 
markers (Rakha and Ellis, 2011; Weigel and Dowsett, 2010). Moreover, the predictive 
markers can represent the target of therapy themselves.  
Pathological factors have mainly a prognostic role, while molecular markers are generally 
used as predictive ones. There are many prognostic and predictive factors, which have been 
suggested for BC, but in this thesis only the most important and widely accepted are 
presented. The clinical-pathological and molecular factors have been incorporated into 
guidelines such as the European St. Gallen Consensus (Gnant et al., 2011; Goldhirsch et al., 
2009; Goldhirsch et al., 2011), the American Society of Clinical Oncology (ASCO) 
guidelines (Hammond et al., 2010; Wolff et al., 2007), as well as in internet-based decision 
tool such as Adjuvant!Online (https://www.adjuvantonline.com) (Mook et al., 2009), to help 
clinicians evaluating the prognosis and the need for adjuvant therapy.  
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1.6.1  Traditional Morphological features 
Traditionally, clinical-pathological features for patient’s prognosis are: the TNM staging 
and the histological grade. Other pathological variables are: histological type, lymph 
vascular invasion, focality of the tumour, presence of in situ lesion, age of patients, family 
history and menopause status (Rakha and Ellis, 2011).  
 
Tumour size 
Tumour size is one of the strongest prognostic features, even after 20 years of follow-up 
(Arriagada et al., 2006). The size is closely related to the frequency of lymph nodes 
metastases. Increment in tumour size is accompanied by a higher probability of having 
lymph node involvement In fact, patients with tumours less than 1 cm in size show node 
positivity in 10% to 20%, at a size of 2 cm 40% of patients are nodes positive which reaches 
50% at a size larger than 2 cm (Rakha and Ellis, 2011). Tumours size is also related to 
patients survival: tumour measuring less than 1.0 cm show a 10 years disease free survival 
rate of 90%, while it declines to 75% for tumours between 1-2 cm, and it falls to 60% for 
tumour of 2-5 cm (Kollias et al., 1997; Rakha et al., 2008a). The precise assessment of 
tumour size is fundamental to properly stratify patients for therapeutic treatments. 
Lymph nodes 
Loco-regional lymph nodes involvement is one of the most important prognostic factors in 
BC. Patients with positive lymph nodes have a 4-8 times higher mortality respect to lymph 
node negative ones (Soerjomataram et al., 2008). Prognosis depends also on the number of 
involved lymph nodes involved: the greater the number the poorer the survival of patients. It 
was also observed that 70% of patients with positive axillary nodes will develop recurrence, 
compared to 15-30% of lymph node negative. The involvement of nodes in the higher levels 
of the axilla, is related to a worse prognosis as well as the involvement of the internal 
mammary nodes. At diagnosis, approximately one third of operable BC patients present 
with positive nodes, of those 7% to 15% having more than 3 positive nodes. (Rakha and 
Ellis, 2011). 
Histological Grade 
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Lower grade tumours are associated to better and longer survival, while higher grade ones 
showed a lower long-term survival. Cumulative 10-years survival, depending also on 
tumour size and nodal status, is about 90% for lower grade and 30-78% for highest score 
(Soerjomataram et al., 2008). Histological grade prognostic value is particularly important 
for the subgroups of BC in which adjuvant chemotherapy decision has to be made, such as 
LN-/ER+/HER2- or in patients with low volume LN metastatic disease (pN1), where the 
decision on the use of chemotherapy cannot be determined as for more advanced tumor 
stages (Rakha and Ellis, 2011). 
Histological Type 
Histological type provides four categories of prognosis: excellent, good, poor and very poor. 
Invasive cribriform, tubular, tubulo-lobular and mucinous have a excellent prognosis, 
showing more than 80% survival at 10 years. Tubular mixed, mixed ductal with special 
type, atypical medullary and alveolar lobular carcinoma present good prognosis with a 60–
80% survival at 10-year. Invasive papillary tumours, classic lobular and medullary cancers 
have worse prognosis. Ductal, solid lobular, mixed ductal and lobular carcinoma have less 
than 50% survival at 10-year, while inflammatory presents 30% survival at 10-years 
(Soerjomataram et al., 2008). Unfortunately the majority of diagnosed BC has no special 
type, as invasive ductal carcinoma. As a consequence, the role of histological type in 
prognostication is still limited (Rakha and Ellis, 2011). 
 
1.6.2  Traditional Molecular markers 
Prognostic and predictive molecular markers routinely used in clinical practice are: 
oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor 
receptor 2 (HER-2). The mitotic index Ki67 is not yet incorporated in clinic, despite its 
important value for measuring proliferation and categorizing patients into different group to 
help tumour classification (Rakha and Ellis, 2011). 
 
Oestrogen receptor (ER) 
ER α is the most important marker in BC, since it is an indicator of response to endocrine 
treatment. ER-positive tumours represent the vast majority of BC (Weigel and Dowsett, 
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2010). These tumours use the steroid hormone estradiol as the main growth stimulus. 
Nevertheless, ER is the direct target of endocrine therapy, which is performed directly using 
oestrogen agonists (i.e. Tamoxifen) or indirectly by blocking the conversion of androgens to 
oestrogen (i.e. aromatase inhibitors). ER status provides mainly predictive information, 
while its prognostic role is limited. In fact, ER-positive tumours are generally well 
differentiated and related to better outcome, but in long-term survival studies ER loses its 
prognostic value (2005). ER assessment defines two groups, the ER-positive and the ER-
negative. Nevertheless in the first group, roughly half patients respond to hormone treatment 
(Rakha and Ellis, 2011; Rakha et al., 2010). ER-negative patients are addressed to other 
systemic treatments. It was also reported that ER-negative patients reached a more complete 
response with neo-adjuvant chemotherapy than ER-positive (Weigel and Dowsett, 2010). 
Progesterone receptor (PR) 
It is an oestrogen-regulated gene and its expression is considered an indicator of the 
function of ER pathway. About 40% of ER-positive tumours are PR-negative, lack of PR 
expression may indicate an aberrant growth factor signalling which could contribute to 
resistance to tamoxifen (Rakha et al., 2010). Studies in patients with metastases and in 
adjuvant trials with tamoxifen showed a better prognostic role of PR (Dowsett et al., 2006; 
Elledge et al., 2000). However tumours expressing PR but not ER are considered not true 
and need to retest the ER to exclude false negativity. 
HER-2 
The prognostic role of amplification of HER-2 in BC was first identified in 1987 (Slamon et 
al., 1987) . After the development of a humanised monoclonal antibody against HER-2 
protein (trastuzumab, Herceptin), the assessment of HER-2 amplification became a strong 
predictive biomarker. Amplification of HER-2 gene and RNA/protein overexpression are 
correlated (Pegram et al., 2000). HER-2 amplification was found in 13-20% of BC, and 
approximately the 55% of these tumours are both ER and PR negative (Rakha et al., 2010). 
The main reason of assessing HER-2 in routine clinical practice is for treatment decision: 
trastuzumab could be addressed to patients with HER-2+ advanced disease and in the 
adjuvant setting for HER-2 early stage (Rakha et al., 2010). HER-2 status may also provide 
information for others systemic therapies, HER-2+ tumours are associated as well to 
resistance to endocrine therapies and poorer response to tamoxifen in ER+ and HER-2+ 
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patients. An association of HER-2+ cancers and benefit from anthracycline-based 
chemotherapy was also demonstrated (Gianni et al., 2009; Muss et al., 1994) 
Ki67 
Ki67 is a nuclear non-histone protein and it is widely used as marker of proliferation, since 
it is universally expressed in proliferating cells and absent in quiescent cells. Ki67 is 
expressed during G1, S and G2 phases with a peak on mitosis, not in G0 phase of cell cycle. 
Many studies showed the ability of this marker as single variable to define good or worse 
outcome in BC patients’ for low and higher Ki67 expression respectively (Cheang et al., 
2009; Delpech et al., 2012; Sarode et al., 2011). However, contrasting results on the role of 
Ki67 in predicting patients’ survival are present in literature, as reported by Stuart-Harris et 
al. who observed an association between Ki67 positivity and shorter survival (Stuart-Harris 
et al., 2008). As a consequence, Ki67 is not still recommended as prognostic marker for 
clinical routine (Weigel and Dowsett, 2010). Anyway, Ki67 is determinant not only for 
patients’ outcome, but it can be used as predictor of response to chemotherapy. A recent 
study proposed a cut-off of 14% for Ki67 to distinguish luminal A from luminal B tumours 
(Cheang et al., 2009). According to this subdivision luminal A patients have been proposed 
to skip chemotherapy treatment because of the low level of proliferation (Goldhirsch et al., 
2011). 
 
1.6.3  Biomarkers under investigation 
Tumour suppressor Retinoblastoma (RB) is a regulator of cell cycle and is inactivated in 
many human cancers (Manning and Dyson, 2012). RB functions as a transcriptional 
modulator through binding to the family of E2F transcription factors. The complex Rb-E2F 
acts as a growth suppressor and prevents progression through the cell cycle. 
Phosphorylation of the protein RB through the complexes of Cyclin-Dependent Kinases 
(CDK) and cyclins inhibits its activity. The majority of breast cancers are ER‑positive at 
diagnosis and, in the process of tumourigenesis, epithelia mammary cells are ER dependent 
for proliferation. Retinoblastoma alterations in breast cancer includes loss of RB expression 
(20-35%) and loss of heterozygosity together with other alterations (7-35%) (Bosco and 
Knudsen, 2007). Some studies reported that loss of RB is correlated to advanced disease and 
often to ER-negative breast cancers (Jares et al., 1997). RB inactivity seems to be, also, 
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determinant for the resistance to hormone therapy (Bosco and Knudsen, 2007). Moreover, 
several approaches that inhibit Cyclin-Dependent Kinase 2 (CDK2) induced the arrest of 
phases S and G2, and determined induction of apoptosis (Shapiro, 2006). Given that 
inhibition of CDK2 and CDK1 may potentiate apoptosis induced by DNA-damaging agents 
that affect S-phase progression or by microtubule stabilizing agents, CDK inhibitors may be 
important in combination therapy (Shapiro, 2006). 
Another widely investigated gene is p53, the most frequently mutated tumour suppressor 
gene in human cancer (Lai et al., 2012). The p53 regulates numerous cellular functions 
including cell cycle progression, apoptosis, senescence, cell motility, DNA repair, genetic 
instability and cell metabolism by activating transcriptionally several genes. The p53 gene is 
altered in 20-40% of breast tumours and its inactivation seems to be an early event in the 
tumourigenesis (Lester, 2010). The most frequent alterations are point mutations, which 
lead to the synthesis of a stable, malfunctioning and non-degradable protein, which is 
accumulated in the cells. Preclinical and clinical studies demonstrated that mutant p53 
cancer cells are more resistant to drugs compared with those with wild-type p53. Therefore 
the role of p53 in mediating a chemotherapeutic response is complex and depends on both 
cellular context and type of therapy. (Lai et al., 2012)  
The PI3K/AKT signalling cascade has emerged as a key regulator of several cancer 
phenotypes, including cell survival, proliferation, angiogenesis and metabolism (Chin and 
Toker, 2009). The PI3K pathway is the most frequently mutated pathway in BC, and it is 
characterized by mutation and/or amplification of PI3K catalytic subunits p110α (PIK3CA), 
p110β (PIK3CB) and the PI3K regulatory subunit p85α (PIK3R1) (Miller et al., 2011). The 
PIK3CA resulted mutated in approximately 30% of human breast cancers, particularly ER-
positive tumours (Toker, 2011). The PI3K oncogenic mutation lead to the hyperactivation of 
its effector AKT, that in turn mediates downstream signalling by the phosphorylation of 
other effector proteins. Furthermore, also the deletion and loss of heterozygosity in the 
tumour suppressors PTEN and PHLPP (PH domain and leucine rich protein phosphatase), 
which inhibit the PI3K/AKT signalling, lead as well to hyperactivation of AKT (Toker, 
2011).  
AKT (also known as protein kinase B) is a serine/threonine protein kinase that plays a key 
role in multiple cellular processes, such as glucose metabolism, apoptosis, cell proliferation, 
transcription and cell migration. Recent studies have demonstrated different and non 
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redundant functions of AKT isoforms that depends on the cell and tissue type (Toker, 2011). 
There are three different isoforms of AKT (AKT1, AKT2, AKT3), which derived from 3 
distinct genes located on three different chromosomes 14q32, 19q13 and 1q44, respectively 
(Chin and Toker, 2009; Toker, 2011; Wickenden and Watson, 2010). AKT1 and AKT2 are 
ubiquitously expressed in cells, while AKT3 is mainly distributed in neuronal tissue (Toker, 
2011). AKT1 seems to play a key role in cell proliferation, survival and differentiation, by 
preventing the epithelial -to- mesenchymal transition (EMT). AKT2 signalling seem to be 
involved mainly in metabolism process. Nevertheless, AKT2 has been shown to enhance the 
migratory and invasive phenotypes of BC cells, by promoting cell adhesion, invasion and 
metastasis (Chin and Toker, 2009). AKT3 role remains unclear. 
All AKT isoforms are activated by similar mechanisms through PI3K signalling (Fig.3). 
Upon stimulation with growth factors, PI3K synthesizes the second messenger 
phosphatidylinositol-3,4,5-triphosphate (PIP3) from the precursor phosphatidylinositol-4,5-
diphosphate (PIP2). PIP3 binds to the Pleckstrin Homology (PH) domain of AKT effectively 
recruiting it to the plasma membrane. The full activation of AKT is reached by 
phosphorylation of two residues (Thr and Ser) in the catalytic domain of the molecule. 
Thr308 (Thr309 for AKT2 and Thr305 for AKT3) is phosphorylated by PDK-1 
(phosphoinositide-dependent-kinase-1). Whereas, the carboxyl-terminal residue Ser473 
(Ser474 and Ser 472 for AKT2 and AKT3, respectively) is phosphorylated primarily by the 
mTORC2 (mammalian target of rapamycin complex 2) complex, even if others mechanisms 
have been suggested, such as PDK-1 phosphorylation, or AKT autophosphorylation. Once 
phosphorylated at these two residues, AKT translocated to distinct subcellular 
compartments and it is able to tranduces cellular signals, by phosphorylating numerous 
substrate proteins. Among the AKT substrates have been identified BAD, MDM2, GSK3β 
(Glycogen Synthase Kinase 3β) and FOXO (Forkhead transcription factors) (Wickenden 
and Watson, 2010).  
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Fig. 3. PI3K/AKT signalling pathway is involved in fundamental cellular processes including protein 
synthesis, proliferation and survival. (DR, death receptor; FOXO, Forkhead family of 
transcription factors; GSK3, glycogen synthase kinase 3; IGF 1/2, insulin-like growth factor 
1/2; IKKβ/2, inhibitor of kappa-B kinase β/2; mTOR, mammalian target of rapamycin; NF-κB, 
nuclear factor-kappa-B; P, phosphate; PDK1, 3-phosphoinositide-dependent kinase 1; PI3K, 
phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol 4,5 diphosphate; PIP3, 
phosphatidylinositol-3,4,5-trisphosphate; PTEN, phosphatase and tensin homologue; S6K, S6 
kinase; TSC1/2, tuberous sclerosis complex 1/2). Adapted from Wickenden and Watson 
(Wickenden and Watson, 2010). 
 
Moreover, cytokeratins (CKs) constitute the largest family of intermediate filaments and are 
epithelial predominant in their expression (Yang et al., 1997). CKs provide a structural role 
in the cell, but they are also involved in signalling networks that regulate functions like cell 
cycle progression, cell size, cellular response to stress, protein synthesis and membrane 
trafficking (Iyer et al., 2013). During the process of malignancy the pattern of CKs 
expression is often maintained (Shao et al., 2012). For this reason the evaluation of CKs is 
performed in diagnostic for the detection of carcinomas (Shao et al., 2012; Yang et al., 
1997). An important characteristic of these molecules is that their expression is regulated by 
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tissue type and differentiation. The epithelial cells of breast duct and lobules comprises two 
major type, namely luminal and basal/myoepithelial cells (Moll et al., 1982). Luminal cells 
form the inner layer that consists of differentiating cells, which are characterized by the 
expression of low weight CKs, as CK7, CK8, CK18 and CK19. The basal/myoepithelial 
cells, that represents the proliferating counterpart of breast epithelia (Iyer et al., 2013), are 
characterized by the expression of high weight CK, as CK5 and CK14 (Moll et al., 1982). In 
addition, the expression of CKs can be evaluated through immunohistochemistry, as 
surrogate marker of gene expression, for the characterization of BC molecular subtypes. 
Vimentin is another member of the intermediate filament family of protein, whose 
expression in cancer has been correlated with accelerated tumour growth, invasion and poor 
prognosis. Vimentin has recently emerged as a marker of epithelial-mesencymal transition 
(EMT), a cellular reprogramming process in which epithelial cells acquire a mesenchymal 
phenotype that causes alteration in cell shape and motility. Increased expression of vimentin 
has been reported in several carcinomas, including breast cancer. Therefore, vimentin 
expression in cancer is likely to become a promising therapeutic target and has great 
potential for providing novel clinical prognostic tools. (Satelli and Li, 2011).  
 
1.6.4 Gene Signature 
In the past decade, the use of high-throughput methods has lead to BC genes signatures. 
Several commercial products have been developed by the use of the abovementioned 
signatures: MammaPrint® (Amsterdam The Netherlands), Oncotype DX® (Redwood city, 
CA, USA), Theros/MGI® (San Diego, CA, USA) and MapQuant DX/simplified (Stamford, 
CT, USA), as reported in Fig. 4. The aim of these prognostic molecular classifiers is double: 
to define subsets of patients with a good prognosis who could forgo chemotherapy, and 
identify individual patients who would benefit from chemotherapy. However, these 
signatures have proven to add limited information to prognostic model based on clinical-
pathological parameters (Colombo et al., 2011). 
MammaPrint® (van 't Veer et al., 2002) is a 70-gene signature for fresh frozen tissues. This 
signature is used to predict node negative BC patients’ outcome within 5 years. This gene 
signature is currently being assessed in prospective phase III clinical trials (Cardoso et al., 
  Introduction 
 
22 
 
2008) and is approved by FDA as prognostic test for patients with age at diagnosis less than 
61 years, with tumour less than 5 cm, lymph node negative and tumour stages I/II.  
The other gene signature that is currently being tested in randomized prospective clinical 
trials is Oncotype DX® (Sparano and Paik, 2008). This assay is a quantitative Real Time 
PCR (qRT-PCR) assay of 21 genes (16 cancer-related and 5 reference genes) for formalin-
fixed paraffin embedded (FFPE) tissues. Oncotype DX® can be used to predict outcome 
and to help therapy decision in ER- positive, node-negative patients. These signatures have 
limited applicability in lymph node positive and ER-negative BC patients (Weigelt et al., 
2010a).  
Theros® is qRT–PCR assay for FFPE tissues, which is commercialized by Biotheranostics. 
In this test the homeobox gene HOXB13 and the interleukin 17B receptor (IL17BR) are 
analysed since the expression ratios between HOXB13 and IL17BR is strongly correlated 
with the development of recurrences (Weigelt et al., 2010a). This test is recommended for 
lymph node negative and ER-positive BC patients, who are treated with surgery alone, to 
define risk of recurrence and benefit from endocrine therapy. However Theros® has not yet 
been shown to predict adjuvant hormone therapy or chemotherapy benefit and has not been 
included in the ASCO or NCCN guidelines for breast cancer treatment (Weigelt et al., 
2010a) 
MapQuant Dx™ Genomic Grade test is a 97-gene expression grade index (GGI) which 
characterizes high-grade vs low-grade tumours, through qRT-PCR. This test could stratify 
histological grade II tumours into GGI low-grade and GGI high-grade, of prognostic 
significance: histological grade II GGI low tumours had outcomes similar to GGI low 
cancers, whereas histological grade II GGI high tumours had outcomes similar to GGI high 
cancers. A high GGI was significantly associated with ‘excellent response to chemotherapy’ 
(Weigelt et al., 2010a). This test was recommended for ER-positive and LN-negative 
patients. This genomic grade test is available under the name MapQuant Dx® by Ipsogen, 
and it is now converted to eight-gene qRT–PCR test (Weigelt et al., 2010a). 
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Fig. 4. Summary of prognostic gene signature available in breast cancer. Taken from Weigelt B et al. 
(Weigelt et al., 2010a) . 
 
1.7 Molecular Classification 
In 2000 Perou et al. (Perou et al., 2000) by cDNA microarray analysis defined an “intrinsic 
gene list” to characterize BC tumours. The analysis was made on 38 invasive breast cancers 
(36 invasive ductal carcinomas and 2 lobular carcinomas), 1 in situ carcinoma, 1 
fibroadenoma, 3 normal breast samples, and numerous replicates from the same patient. 
Hierarchical cluster analysis using this “intrinsic gene list” revealed the existence of four 
molecular BC subtypes, which were substantially different at transcriptomic level (Fig.5). 
The subtypes were: luminal, HER2+, basal-like and normal breast-like (Perou et al., 2000). 
A subsequent study performed by the same group on a larger cohort of patients, showed that 
the luminal group could be further divided into at least two groups: luminal A and luminal B 
(Sorlie et al., 2001). Moreover, Sorlie et al. demonstrated that breast tumours fall into two 
large molecular classes which correspond mainly to the status of oestrogen receptor 
expression: ER-positive and ER-negative. The difference between these two BC classes is 
consistent with the hypothesis that they derive from different tumour progenitor cells 
(Pfeffer et al., 2009). 
The ER-positive (ER+) branch contains luminal subtype that expresses ER, cytokeratin 8 
and 18, characterising luminal epithelial cells of the mammary gland. Luminal A cases are 
mostly low grade tumours and express low levels of proliferation-related genes; contrarily 
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luminal B tumours are usually higher grade and express more likely proliferation-related 
genes (Weigelt et al., 2010a).  
The ER-negative (ER-) branch comprises more heterogeneous subtypes. The first is the 
HER-2 amplified subtype (HER-2+), which is characterised by the overexpression and 
amplification of HER2 gene and the absence of hormone genes expression (ER-, PR-). 
Basal-like tumours are ER, PR and HER-2 negative, but they express CK5/6 and CK14 
typically present in the basal epithelia cells, and/or they could present the amplification of 
Epidermal Growth Factor Receptor (EGFR) (Rakha et al., 2008b). Normal breast-like 
tumours in the analysis of Perou, was characterized by the high expression of basal 
epithelial cells and adipose cells, with low expression of genes specific of luminal epithelial 
cells (Perou et al., 2000). To date the normal breast-like subtype is still under debate, 
because some considered it an artefact of sample representation (higher normal breast cells 
counterpart in frozen fresh tissues) (Colombo et al., 2011; Parker et al., 2009; Weigelt et al., 
2010a).  
In addition, other three molecular groups in ER-negative branch have been identified: the 
‘molecular apocrine’, similar to the HER2+ subtype, but it showed activation of androgen 
receptor; the ‘interferon-rich’, characterized by higher expression of interferon-regulated 
genes; and the ‘claudin-low’ which comprises tumours that express low level of claudin 
mRNA, lack of expression of E-cadherin and higher expression for genes typically activated 
in the epithelial-mesenchimal transition (EMT) process (Colombo et al., 2011).  
First Sorlie et al. in 2001 (Sorlie et al., 2001), and more recently a lot of other groups 
(Parker et al., 2009; Rakha and Ellis, 2011; Valentin et al., 2012; van de Rijn et al., 2002; 
Weigel and Dowsett, 2010; Weigelt et al., 2010a) demonstrated that these molecular 
subtypes are related to different outcomes. Among luminal tumours, the luminal A showed 
a better prognosis in comparison to luminal B. HER-2 and basal-like present an aggressive 
behaviour as well as worse prognosis. The clinical significance of normal breast-like 
tumours has yet to be determined.   
The use of molecular classification by microarray is limited in clinical practice, because 
gene expression profiling is applied on fresh tissues, is expensive and is technically 
complex. For these reasons, investigators started to use surrogate markers to obtain 
molecular classification using immunohistochemistry (IHC). It has already been shown that 
data originating from mRNA expression profiling correlate with those obtained by IHC 
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(Gruver et al., 2011; Muller et al., 2011; Rakha and Ellis, 2011). However to date, a 
consensus on the definition of the panel of markers to be used in molecular classification 
has not been reached, as well as the clones of antibodies and the threshold cut-off for 
positivity (Geyer et al., 2012; Tang et al., 2009). 
Some pathologists have used simply ER, PR, HER-2 and histological grade to classify 
breast tumours into luminal, HER-2 amplified and triple-negative (TN) (Muller et al., 2011; 
Wiechmann et al., 2009). The TN phenotype is commonly used as a surrogate for basal-like 
tumours. However, others have also used the proliferation markers Ki67 (Cheang et al., 
2009) or the basal cytokeratins, to identify the basal-like subtype (Nielsen et al., 2004).  
The PAM50 RT-qPCR assay is a single sample predictor for the molecular subtypes and 
may provide a way of incorporating the molecular subtypes in the diagnosis and 
prognostication of breast cancer patients (Parker et al., 2009). However this assay presented 
only a modest agreement between IHC/fluorescence in situ hybridization (FISH) defined 
HER2-positive cases and PAM50-defined HER2-positive cases (Weigelt et al., 2010a), that 
could lead to a possible misclassification of HER-2+ tumours. 
 
Fig. 5. Dendogram of the five major clusters belonging to BC molecular classification. The dendogram 
is divided in two main branches that represent the ER-negative (ER-ve) and ER-positive 
(ER+ve) tumours. Adapted from Sorlie et al. (Sorlie et al., 2001). 
 
1.8 Therapeutic Treatment 
The clinical management of breast cancer has been significantly changed over the last few 
decades. Most women with breast cancer are surgically treated, and sometimes they are 
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submitted also to other treatments such as radiation therapy, chemotherapy, hormone 
therapy, and/or targeted therapy. In the past, the first step for BC treatment was surgery, 
nowadays neo-adjuvant therapy has been widely accepted and utilised (Downs-Holmes and 
Silverman, 2011). Here an overview of the available treatments for BC patients has been 
reported, according to National Comprehensive Cancer Network (NCCN) 
(http://www.nccn.org/professionals/physician_gls/f_guidelines.asp) and American Cancer 
Society (ACS) (http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-
treating-general-info) guidelines.  
 
 
Surgery  
The main goal of surgery is the removal of the cancer from the breast and the assessment of 
tumour stage. Surgery includes breast conserving treatment and mastectomy. Breast 
conserving surgery is not recommended when the tumour presents extensive involvement, 
or in case of inflammatory component, or multifocal disease (Downs-Holmes and 
Silverman, 2011). On the other side, mastectomy does not give better long-term survival if 
compared to breast conservation surgery (Veronesi et al., 2002). In women with no evidence 
of lymph node involvement before surgery sentinel lymph node biopsy has been used 
(Veronesi et al., 2003), but recently oncologists are considering the possibility of abolish the 
SLN biopsy. For many years sentinel lymph node (SLND) and axillary lymph node 
dissections has been the surgical standard for patients with positive sentinel lymph nodes 
(SLNs). However, since removal of many lymph nodes increases the risk of lymphedema 
after surgery, SLND without axillary dissection is suggested for patients with one or two 
positive sentinel nodes and tumours less than 5 cm (Downs-Holmes and Silverman, 2011). 
Axillary lymph node dissection (ALND) is mandatory for patients submitted to mastectomy 
(http://www.nccn.org/professionals/physician_gls/f_guidelines.asp), for patients with 
voluminous axillary disease, for tumours greater than 5 cm, after neo-adjuvant treatment, 
and in cases in which partial breast radiation or no radiation is planned (Downs-Holmes and 
Silverman, 2011). 
Radiation therapy 
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It is used to destroy cancer cells remaining in the breast, chest wall, or underarm area after 
breast-conserving surgery. Radiation may also be needed after mastectomy in patients with 
either a cancer that is larger than 5 cm in size or when cancer is found in more than 3 lymph 
nodes (http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-treating-
general-info; Truong et al., 2005). There are two types of radiation: external beam radiation, 
the usual for BC, and internal radiation therapy, also known as brachytherapy. In external 
radiation therapy the whole breast is usually irradiated but, depending on the size and extent 
of the cancer, it could also be irradiated the chest wall as well the underarm area. Internal 
radiation therapy consists of a radioactive substance sealed in needles, wires or catheters, 
which are placed directly into or near the cancer. The way the radiation therapy is given 
depends on the type, stage, and location of the tumour being treated. 
Systemic therapy 
Systemic therapy includes chemotherapy, hormone therapy, targeted therapy. Systemic 
therapy could be given as neo-adjuvant or adjuvant treatment. Neo-adjuvant treatment, 
before surgery, is administered to patients to improve operability for locally advanced 
disease and the chance of breast conservation for larger tumours (Downs-Holmes and 
Silverman, 2011). Systemic therapy given to patients after surgery is called adjuvant 
therapy. In this case, after surgical removal, adjuvant therapy is used to kill any undetected 
tumour cell that may have been left behind or migrated to other parts of the body. Moreover, 
systemic therapy is the main treatment for patients with metastatic BC who cannot 
underwent surgery.  
The benefit of chemotherapy is dependent on multiple factors, such as tumour size, lymph 
node involvement, ER, PR, HER-2 status. Many combinations of drugs are being used. In 
early BC the most common regimens comprises cyclophosphamide, methotrexate, 
fluorouracil, doxorubicin, epirubicin, paclitaxel, and docetaxol. These and other 
chemotherapeutical drugs can be used in metastatic setting. 
ER positive patients may be submitted to hormone therapy. This therapy is mostly used as 
adjuvant therapy to help reduce the risk of the recurrences after surgery, but it can also be 
given as neo-adjuvant treatment. There are two classes of hormonal agents for BC: selective 
ER modulators (SERMs) and aromatase inhibitors (AIs) (Downs-Holmes and Silverman, 
2011). Tamoxifen and toromifene are SERMs, they prevent the binding of oestrogen to BC 
cells and are mainly given to premenopausal women. Conversely, letrozole, anastrozole and 
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exemestane are AIs. This class of drug can be used both in early and advanced disease, but 
it is effective only for postmenopausal women. AIs block the aromatase enzyme in fat 
tissue, which is responsible for the production of small amounts of oestrogen in 
postmenopausal women. It was demonstrated that postmenopausal women receive more 
benefit from AIs than tamoxifen in the adjuvant setting (Downs-Holmes and Silverman, 
2011). Other options for patients who do not respond to tamoxifen or AIs are Fulvestrant 
and Androgens. 
‘Targeted therapy’ refers to drugs that specifically target some molecules, with fewer side 
effects. Tratuzumab is a monoclonal antibody that targets the HER2 protein in breast tumors 
and offers a survival benefit for women with breast cancer that overexpresses HER-2, both 
in early and metastatic BC (Slamon and Pegram, 2001; Slamon et al., 2001). A recent study 
showed that the addition of trastuzumab to the standard chemotherapy in early BC 
overexpressing HER-2 reduced the risk of recurrence and death of 52% and 33%, 
respectively, in comparison with chemotherapy alone (Romond et al., 2005). In 2006 FDA 
approved trastuzumab for treatment of positive HER-2 breast tumours. Lapatinib is another 
drug which targets HER-2 protein, and has been found effective in patients with advanced 
disease resistant to trastuzumab 
(http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-treating-general-
info).  
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2 AIM OF THE STUDY 
Breast carcinoma encompasses a heterogeneous group of tumours with a great variability at 
the morphological and molecular level as well clinical outcome (Rakha and Ellis, 2011). In 
spite of the recent advances both in the knowledge of molecular mechanisms leading to BC 
initiation and in clinical management, a significant number of patients presenting similar 
histological and pathological features can show very distinct outcomes. Therefore the aim of 
this thesis is the identification and validation of new prognostic biomarkers in a 
retrospective case study of patients affected by primary breast carcinoma with a long 
follow-up.  
In its first part this thesis investigates the role of BC molecular classification in patients’ 
prognosis and prediction of clinical outcome, by comparing the traditional pathological 
factors with the emerging molecular classes. Molecular classification was assessed by 
means of immunohistochemistry, using seven surrogate markers (ER, PR, HER-2, Ki67, 
CK8, CK5/6 and vimentin), in a case study of 305 patients, divided in lymph node negative 
(LN-) and lymph node positive (LN+). Molecular characterization was also performed in 
some regional metastatic lymph nodes, in order to evaluate the phenotype of the cells that 
colonise the lymph nodes in the process of metastatization. 
In the second part gene expression analysis of nine candidate prognostic biomarkers was 
performed. The genes of interest belong to the RB pathway (RB and CDK2), RAS pathway 
(HER-2, PI3K, AKT1, AKT2, AKT3, RAF1) and cellular differentiation mechanism (CK8). 
Gene’s expression was investigated in the entire cohort of primary tumours of the case 
study. Genes were chosen to confirm our previous studies (Bonin et al., 2008; Bonin et al., 
2006), which revealed that seven genes seemed to be involved in patient’s prognosis. In the 
present thesis the potential prognostic role of 9 candidate genes was investigated at mRNA 
level through Real Time PCR. Comparison of genes expression was performed with respect 
to lymph node involvement and molecular classification to better characterise biological 
heterogeneity and clinical outcome of the molecular subtypes. 
In both parts of the thesis, molecular analysis was performed on formalin fixed and paraffin 
embedded (FFPE) tissues specimens, in order to directly compare experimental results with 
clinical data. 
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3 MATERIALS AND METHODS 
3.1 Patients and Sample Collection 
The retrospective study carried out in this project was performed on a cohort of young 
women comprising both lymph node negative (LN-) and lymph node positive (LN+) breast 
cancer patients. The criteria for patients’ selection were: i) women who had stage I-III 
invasive BC, ii) age at diagnosis 55 years or younger, iii) absence of a second primary 
breast cancer or other malignancies, iv) No anticancer treatment prior surgery, v) and 15-25 
years of follow-up-information if alive. Women were all resident in the North-Eastern 
province of Trieste and had a diagnosis of primary breast cancer established between 1st 
January 1983 and 31st December 1993. By applying these criteria 380 women were 
enrolled. Patients with in situ BC and cases without tissue availability for microdissection of 
tumour (i.e. absence of tumour block or needle aspiration biopsies) were excluded from the 
study. Therefore, 305 patients were included in the study, 151 LN- and 154 LN+. FFPE 
tissues of the primary tumour referred to surgical treatment and a representative number 
(100) of loco-regional metastastic lymph nodes were used for the analyses. Patients were 
treated with radical mastectomy, modified radical mastectomy or breast-conserving surgery. 
All patients submitted to conserving surgery were treated with radiotherapy. In detail, in 
patients LN- or LN+ with 3 or less lymph nodes involved, only the breast was irradiated; on 
the other hand in patients with more than 3 metastatic lymph nodes and capsule invasion, 
breast and axilla were irradiated. All LN+ patients were treated with adjuvant chemotherapy 
with CMF (cyclophosphamide, methotrexate, fluorouracil) or EC/ECF (epirubicin, 
cyclophosphamide, fluorouracil) regimens according to standard protocols. ER-positive 
patients, both LN- and LN+, were submitted to hormone therapy with Tamoxifen.  
Cases were enrolled before the collection of follow-up data. Patients were followed up from 
the date of diagnosis of BC to death or until 31 December 2008, whichever came first. 
Clinical end-point of the study was overall survival (OS) that was defined as the time from 
surgery to breast cancer specific death. The cohort of patients was followed through the 
general population-based Friuli Venezia Giulia Cancer Registry. 
Clinical information such as type of surgery, tumour stage, TNM classification, presence of 
recurrence, patient’s status and cause of death were obtained from medical records. 
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3.2 Histological Revision 
Hematoxylin-eosin (H&E) staining was performed on 4 µm-thick FFPE tissue sections for 
all the case study according to the standard procedure (Melis, 1975). H&E slides were 
reviewed by a pathologist. Histological revision was performed to evaluate the histological 
type of tumour according to the World Health Organization (WHO 2003) (Ellis et al., 
2003), and histological grade according to Elston and Ellis grading system (Elston and Ellis, 
1991).  
Finally, the pathologist defined for each H&E slides, both primary tumour and metastatic 
lymph node, the representative tumour areas that were later used for molecular analysis. 
 
3.3 Microdissection 
3.3.1 Manual Microdissection 
Manual microdissection was performed to isolate tumour from perilesional tissue in cases 
where the amount of perilisonal tissue was higher than 15% of the total amount. The areas 
of interest were identified on a reference H&E-stained section and then mechanically 
microdissected on the paraffin block For each sample, five-twenty consecutive unstained 5 
µm-thick sections were cut, depending on the size of tissue area (Faoro and Stanta, 2011). 
Later, dissected specimens were deparaffinised in xylene and rehydrated in ethanol for 
nucleic acids or protein extraction (Bonin and Stanta, 2011; Stanta et al., 1998). 
 
3.3.2 Tissue Microarray (TMA)  
Microdissection of tumours was performed with the Tissue Microarray (TMA) technique 
both for immunohistochemical analysis and RNA extraction. The procedure of TMA 
construction was similar for these purposes, the difference was limited to the needle 
diameter involved: 1 mm for IHC assay and 3 mm for RNA extraction. TMAs were 
constructed using the FFPE tissues of the entire cohort, dissecting from the selected tumour 
areas that were marked on the H&E slides. 
For IHC purposes, tissue cylinders of 1 mm diameter were taken from the selected regions 
of the donor paraffin block and were punched into a recipient paraffin block using a tissue-
arraying instrument (Galileo TMA CK3500, Integrated Systems Engineering, Milano, 
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Italy). Regarding primary tumours, 8 tissue arrays containing 384 spots were built to 
assemble the 305 BC patients. In detail one representative spot for each patient was taken. 
Multiple tissue cores were sampled if: the tumour presented histological heterogeneous 
regions, or the tissue spot was not evaluable in subsequent IHC. For the analysis of 
metastatic lymph nodes, one representative spot was sampled. Accordingly, three TMAs 
with 102 tissue core were assembled. Once prepared, TMA was placed upside-down onto a 
glass slide and incubated at 40°C for about 45 minutes to allow binding of the donor cores 
to the paraffin wax of the block (Faoro and Sapino, 2011). The glass slide was used to level 
the block surface by gently pushing the cores into the block. After cooling, 4 µm thick 
sections were cut, mounted on Superfrost® Plus (Thermo Scientific) microscope slides and 
heated at 37°C overnight for subsequent IHC analyses.  
For RNA extraction, 3 mm tissue core was taken from areas adjacent to the previously 
extracted punches and inserted into a new recipient block, for each tumour. After melting 
paraffin wax and core tissues and subsequent cooling as above mentioned, 20 sections of 5 
µm thickness were cut for each punch and placed into a new 1.5 ml tube. 
 
3.4 Molecular Analysis at Protein Level 
3.4.1 Immunohistochemical Staining 
The IHC staining was performed on 4 µm-thick tissue sections of the TMA blocks. The 
antibodies used and the experimental conditions are listed in the table below (Table 4). The 
immunostaining procedures were performed manually using the Vectastain Universal Elite 
ABC kit (Vector Laboratories) for the antibodies: ER, PR, HER2, cytokeratin 8 (CK8), 
cytokeratin 5/6 (CK5/6) and vimentin. Incubations were performed in a humidified 
chamber. Briefly, tissue sections were deparaffinised in xylene for 30 minutes and then 
hydrated in a decreasing alcohol series (100%, 96% and 50%). Endogenous peroxidase 
activity was blocked by incubating the tissue sections in 0.3% hydrogen peroxide solution 
(Sigma-Aldrich) for 10 minutes. Heat mediated antigen retrieval was performed in water 
bath at 120°C, with low and high pH buffer for 20 minutes. To avoid unspecific binding, the 
sections were incubated for 20 minutes with blocking serum (Vectastain Universal Elite 
ABC kit, Vector Laboratories). Incubation with the primary antibody was performed for 1 
hour as described in Table 3. The slides were washed three times for 3 minutes each in PBS 
and 0.1% Triton X-100 (PBST), incubated for 60 minutes with the biotinylated secondary 
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antibody and for 30 minutes with Vectastain ABC system. Slides were washed three times 
in PBST. For the visualization Dab Substrate kit for Peroxidase (Vector Laboratories) was 
used. Finally, sections were counterstained with Mayer’s Hematoxilin (Bio Optica). Positive 
and negative controls were used in each IHC assay. Positive control slides from BC tissues 
were employed for ER, PR, Her2 and Ck8 staining; while slides obtained from tonsil was 
used for Ck5/6, Vimentin and Ki67 antibodies. Negative controls were prepared using the 
same TMAs slides, without the primary antibody incubation. 
Immunostaining for Ki67 and HER-2 were performed in Lab Vision Autostainer 480S 
(Thermo Scientific) with the UltraVision LP Large Volume Detection System HRP Polymer 
(Lab Vision Corporation, Thermo Scientific) according to manufacturer’s protocol. In brief, 
after deparaffinisation and rehydration steps, tissue sections were washed two times in 
0.05M TBS + Tween 20 (Bio-Optica) buffer. Tissue slides were treated with high pH 
antigen retrieval for 20 minutes in heated water bath and washed 4 times in buffer. To 
reduce non-specific background staining, endogenous peroxidase was blocked with 
hydrogen peroxide for 10 minutes. After 4 washes, the primary antibody was applied; 
subsequently tissue sections were incubated with primary antibody enhancer for 20 minutes 
at room temperature. After washing, the HRP Polymer was applied for 30 minutes at room 
temperature. For visualization the chromogen 3,3' Diaminobenzidine (DAB) (LabVision, 
Thermo scientific) was used. The sections were counterstained with Mayer hematoxylin as 
usual.  
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Primary 
antibodies 
Clone 
source 
Localization Antigen retrieval Diluition Incubation 
ER SP1 Ventana nucleus 
0.1 M Tris-Borate 
1mM EDTA pH8 
(120° C water bath, 20 
minutes) 
PD 1 hour RT 
PR 1E2 Ventana nucleus 
0.1 M Tris-Borate 
1mM EDTA pH8 
(120° C water bath, 20 
minutes) 
PD 1 hour RT 
HER-2 
CB11 
Thermo 
Scientific 
membrane 
0.1 M Tris-Borate 
1mM EDTA pH8 
(120° C water bath, 20 
minutes) 
1:300 30 minutes RT 
Ki67 MIB1 Dako nucleus 
0.1 M Tris-Borate 
1mM EDTA pH8 
(15 minutes MW) 
1:200 30 minutes RT 
CK 8 M20 Abcam 
Cytoplasm/ 
membrane 
10 mM buffer Citrate 
pH6 (120° C water 
bath, 20 minutes) 
1:250 1 hour RT 
CK 5/6 
D5&16B4 
Aczon 
biotech 
Cytoplasm/ 
membrane 
0.1 M Tris-Borate 
1mM EDTA pH8 
(120° C water bath, 20 
minutes) 
1:100 1 hour RT 
Vimentin V9 Ventana 
Cytoplasm/ 
membrane 
10 mM Citrate buffer 
pH6 (120° C water 
bath, 20 minutes) 
PD 1 hour RT 
Table 3. Primary antibody used for IHC analysis. PD=prediluted, RT=room temperature 
 
3.4.2 Evaluation of Immunohistochemistry and Definition of Molecular Classes 
Immunostaining was evaluated using the light microscopy, counting the positive cells across 
three high power fields (HPF) at 40X magnification by two different observers in a blinded 
fashion. The mean values were used for analyses.  
Semi-quantitative evaluation of each antibody staining was scored according to the intensity 
of the signal and by assessing the percentage of immunoreactive tumour cells in a high 
magnification field over the total number of tumour cells in that magnification field. The 
intensity of the signal for each antibody was categorized into 4 groups (0-3), namely no 
expression, weak expression (1+), moderate expression (2+), or strong expression (3+). 
Tumours were considered positive for ER and PR if more than 10% of tumour nuclei were 
stained (Li et al., 2011; Muller et al., 2011). HER-2 expression was scored according to 
ASCO guidelines using the following criteria: 1+, a faint and incomplete membranous 
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staining for HER-2 in more than 10% of cells was considered as negative; 2+, a complete 
membranous staining, either non-uniform or weak in at least 10% of cells; score of 3+ when 
complete membrane staining intensity in more than 30% of cells was present (Wolff et al., 
2007). HER-2 results were considered positive in cases of 3+ immunohistochemical 
staining. A score of 2+ was interpreted as equivocal and automatically analysed for gene 
amplification through silver in situ hybridization (SISH), as described in the next paragraph. 
Tumours positive in more than 10% of cells were defined positive for CK8, CK5/6. 
Vimentin was considered positive if more than 1% of cancer cells were stained. For Ki67 
samples were scored by counting the percentage of positive cells and stratified into two 
groups according to their proliferation activity: 0-14% were classified as low proliferation 
index (<14%), and ≥14% as high proliferation index, according to St. Gallen consensus 
(Cheang et al., 2009; Goldhirsch et al., 2011). 
The tumours were then classified into four main molecular classes according to the staining 
profile of the antigen markers: ER, PR, HER-2, CK8, CK5/6, Ki67 (Cheang et al., 2009; 
Dawood et al., 2011; Goldhirsch et al., 2011; Gruver et al., 2011; Park et al., 2012). In 
detail, cases: 
• ER+ and/or PR+, HER-2-, low Ki67, CK8+ were classified as Luminal A;  
• ER+ and/or PR+, HER-2-, high Ki67 or ER+ and/or PR+, HER-2+, any Ki67 were 
classified as Luminal B;  
• ER-, PR-; HER-2+, any Ki67 were defined HER-2 type;  
• ER-, PR-, HER-2-, CK5/6+, any Ki67 were classified as basal-like.  
The expression of vimentin, was studied in the entire cohort.  
Tumours which did not meet the above mentioned panel criteria, were defined as 
‘unclassified’. 
In Fig. 6 are shown the pictures of positive staining for each primary antibody. 
 
3.4.3 Silver In Situ Hybridization (SISH) 
It is used to quantitatively detect HER-2 gene amplification for cases classified as 2+ in 
IHC. SISH analysis was performed using the ultra View SISH DNP Detection Kit (Ventana 
Medical System) in Benchmark XT automated slide stainer instrument, according to 
manufacturer’s instruction. The Pathway HER-2/neu DNA Probe (Ventana) and HER-2/neu 
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Region of Chromosome 17 (Ventana), both labelled with dinitrophenol (DNP) were used. In 
brief, slides of microarray block were deparaffinised in xylene, and subsequently rehydrated 
in graded alcohol. Afterwards, tissue sections were pre-treated with heating and/or 
enzymatic digestion. For denaturation, slides were heated to 95° C for 12 minutes and 
hybridization was performed at 52° C for 2 hours. After hybridization, appropriate 
stringency washes with 2X SSC (0.3M NaCl, 0.03M Na citrate pH 7.0), 50% formamide 
were performed 3 times at 59°C. HER-2 DNA probe and Chromosome 17 (Ventana), both 
labelled with dinitrophenol (DNP), were detected using the Rabbit anti-DNP primary 
antibody (ultra View SISH DNP Detection Kit) incubating at 37°C for 20 minutes. 
Evaluation of signal was carried out using a goat anti-rabbit antibody conjugated to 
horseradish peroxidase (HRP) for 16 minutes at 37° C. The chemistry of the SISH reaction 
is driven by the sequential addition of silver acetate, hydroquinone and H2O2. The silver 
ions (Ag+) are reduced by hydroquinone to metallic silver atoms (Ag). The silver 
precipitation is deposited in the nuclei and a single copy of the HER2 gene is visualized as a 
black dot. Finally, slides were counterstained with hematoxylin. 
Counting was performed as recommended by the ASCO/CAP guidelines (Wolff et al., 
2007), a copy number greater than 6 or HER-2 gene/chromosome 17 copy number ratio 
higher than 2.2 was considered positive. A representative picture of SISH for the two probes 
is reported in Fig. 7.  
 
3.5 Molecular Analysis at RNA level 
3.5.1 RNA Extraction from FFPE 
Total RNA was extracted from FFPE specimens of primary breast carcinomas using a 
proteinase K-based protocol (Bonin and Stanta, 2011; Stanta et al., 1998). Sections were 
then deparaffinised in xylene for 30 minutes, and rehydrated in graded ethanol (100%, 96% 
and 50%) for 2 minutes twice. Samples were then digested in 150-400 µl of RNA digestion 
buffer containing 6 mg/ml proteinase K, 1.12 M Guanidine thiocyanate, 20 mM Tris HCl 
pH 7.5, 0.5% N-Lauroyl Sarcosine, 40 mM β-mercaptoethanol at 55°C overnight in a 
thermomixer (Eppendorf). Total RNA was purified by acid phenol/chloroform (Sigma-
Aldrich) extraction followed by ethanol precipitation. Total RNA was resuspended in an 
appropriate volume of DEPC treated water (15 - 30 µl, depending on the amount of starting 
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tissue). Total RNA concentration was assessed through spectrophotometer reading 
(Amersham Biosciences). RNA extracts were stored at -80°C in aliquots. 
 
3.5.2 DNase Treatment and Reverse Transcription (RT) 
To avoid false positive caused by genomic DNA (gDNA) amplification in RT-PCR-based 
analysis, gDNA should be removed by DNase digestion. DNase treatment was performed in 
RNA extracts as already reported (Dotti and Bonin, 2011). Briefly, 4 µg of total RNA were 
digested with RNase free DNase for 15’ at 25°C in 20 µl final volume containing 5U of 
DNAse I (GE Healthcare) and 1X DNase buffer (40 mM Tris-HCl, pH 7.5, 6 mM MgCl2). 
The enzyme was blocked with 2 µl of 25 mM EDTA and heat inactivated at 65°C for 10’.  
DNase treated RNAs were reverse-transcribed into cDNA using Moloney Murine leukemia 
virus (MMLV) reverse transcriptase and random hexamers as already reported (Nardon et 
al., 2009). In detail, 1.2 µg of total digested RNA was added to 3.35 nmoles of random 
examers in a final volume of 9 µl. The mixture was incubated at 65°C for 10 minutes and 
then immediately chilled on ice. At this point 11 µl of the RT mixture were added, yielding 
a final concentration of 1X First Strand Buffer (50 mM Tris-HCl pH 8.3; 75 mM KCl; 3 
mM MgCl2 - Invitrogen), 10 mM DTT (Invitrogen), 4 units of Rnase Inhibitor (Promega) 
4.5 mM MgCl2, 1mM dNTPs (Amersham) and 250 units of MMLV enzyme (Invitrogen). 
The mixture was left at room temperature (25°C) for 10 minutes to allow the annealing of 
the random hexamers, then reverse transcription was carried out at 37°C for 50 minutes. 
Subsequently, enzyme was blocked by heating at 70°C for 10 minutes. Complementary 
DNA was stored at -20°C in aliquots. 
 
3.5.3 Gene Expression 
Genes of interest are: RB and CDK2 (RB pathway), HER-2, PI3K, AKT1, AKT2, AKT3, 
RAF1 (RAS pathway) and CK8. Gene expression analysis was performed by real-time PCR 
using the TaqMan chemistry in the instrument Mastercycler® ep Realplex (Eppendorf, 
Hamburg, Germany).  
For every target gene intron-spanning primers were designed. Amplicon lengths were 
between 60 and 100 base pairs. Primer and probe sequences were built by the use of Primer 
Express software (Applied Biosystem, Darmstadt, Germany) and PrimerQuest software 
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(Integrated DNA Technologies). The details regarding primer/probe sequences and reaction 
conditions are reported in Table 4. Amplification conditions (temperature of annealing and 
MgCl2 concentration) were set up using a cDNA pool of the case study. Subsequently, a 
calibration curve was made for each gene using the cDNA pool with six 1:4 serial dilutions, 
starting from 250 ng of cDNA. Efficiencies of real time amplification, for each gene, were 
checked plotting Ct values of PCR amplified serial dilutions of cDNAs, against the log10 of 
the theoretical initial RNA input. Efficiency was defined as [10^(-1/slope)-1] x100, where the 
slope is obtained from the linear regression line fitted thought the determined points. To 
correct for quantification errors depending on differences in sample-to-sample RNA quality, 
β-Actin was chosen as reference gene for normalization.  
Each PCR assay was performed in duplicate using the JumpStartTMTaq ReadyMixTM For 
Quantitative PCR (Sigma-Aldrich, St. Louise, USA) according to the manufacturer’s 
instructions. In each run respectively 30 ng (β-ACTIN, CDK2, HER-2, AKT3), 40 ng 
(RAF1), 50 ng (AKT2), 60 ng (RB, PI3K, AKT1) of cDNA were used in a final reaction 
volume of 20 µl, containing the JumpStart Ready Mix, the ROX reference dye, the adjusted 
MgCl2, the forward and reverse primer (0.3 µM), the MGB probe labelled with FAM dye 
(0.2 µM). The cycle condition were: one step of 10 minutes at 95°C for denaturation and 
polymerase activation, followed by 45 cycles of two-step program of 15 seconds at 95°C for 
denaturation and 1 minute at 60°C for annealing/extension. To exclude contamination, 
negative controls without cDNA were included in each assay. RNA extracted from the 
breast cancer cell line MCF-7 was used as positive control.  
Genes expression levels were normalized against the chosen housekeeping gene and 
expressed as ratio according to the ∆∆Ct model as previously reported (Pfaffl, 2001).  
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Gene Primer Sequences Product size (bp) MgCl2 (mM) 
PCR 
efficiency 
β-ACTIN 
F: CGGCCCCTCCATCGT 
R: AAAGGGTGTAACGCAACTAAGTCAT 
P: CACCGCAAATGCTTC 
66 1.5 106% 
RB 
F: TCCCATGTTGCTCAAAGAACCA 
R: CCGTGCACTCCTGTTCTGA 
P: TCACCTCGAACACCC 
94 1.5 100% 
CDK2 
F:  CCTCCCCTGGATGAAGATGGA 
R: CCGCTTGTTAGGGTCGTAGTG 
P: CAGCATTTGCGATAACAA 
66 1.5 100% 
HER-2 
F: AGCGCTTTGTGGTCATCCA 
R: GCAGTGAGCGGTAGAAGGT 
P: CCCAGCCAGTCCCTTG 
75 1.5 110% 
PI3K 
F:  TGCCGAGAGATTTTCCCACAAT 
R: CCTGAAGCTGAGCAACATCCT 
P: ATTGACAGCAGTAATTTT 
85 1.5 101% 
AKT1 
F: CCACTGTCATCGAACGCACCT 
R: CACAGTCTGGATGGCGGTTGT 
P: ATGTGGAGACTCCTGAAG 
77 2 88% 
AKT2 
F: AAGCAGAGGCTTGGTGGG 
R: TTGATGCTGAGGAAGAACCTG 
P: CCAGCGATGCCAAGGAGG 
71 2 96% 
AKT3 
F:  TCGAGAGAGCGGGTGTTCT 
R: TGTAGATAGTCCAAGGCAGAGACAA 
P: ACGTGTGCGGTCCTC 
77 2.5 102% 
RAF1 
F:  TCAGGAATGAGGTGGCTGTTC 
R:  TGTACCCCATGAAAAGCAGAA 
P: CGCAAAACACGGCATG 
66 1.5 104% 
CK8 
F:  GGCTCCAGGCTGAGATTGAG 
R: GCTCGGCATCTGCAATGG 
P: CCAGAGGGCTTCCC 
72 1.5 86% 
Table 4. Primers and MGB Probe sequences, condition of reactions and efficiency of Real Time 
analysis. (F: Forward, R: Reverse, P: Probe). 
 
3.6 Cell lines 
Cell lines cultures were used for to settting up the PCR conditions for candidate genes. 
According to the molecular classification, three human BC cell lines were selected: MCF-7, 
SKBR-3 and MDA-MB-231. Briefly, MCF-7 is an oestrogen dependent epithelial breast 
cancer cell line, which expresses also progesterone and androgen receptors and it is 
classified as luminal A subtype (Soule et al., 1973). SK-BR-3 is a breast cancer epithelial 
cell line that is characterized by the overexpression of the HER2 gene product. MDA MB-
231 is an oestrogen receptor independent breast cancer epithelial cell line and it is classified 
as basal-like (or triple negative) subtype. (http://www.lgcstandards-
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atcc.org/ATCCCulturesandProducts/CellBiology/CellLinesandHybridomas/tabid/981/Defau
lt.aspx). 
Cells were cultured in adhesion and maintained in low glucose Dulbecco’s modified Eagle’s 
Medium (DMEM) with L-glutamine (Euroclone S.p.A, Pero Milano, Italy), supplemented 
with 10% (v/v) fetal bovine serum (FBS; Euroclone), 100U/ml penicillin and 100 µg/ml 
streptomycin (Euroclone), 3 µg/ml Gentamicin. Cells were grown at 37°C in an incubator 
supplied with 5% CO2. Confluent monolayer cells were washed with phosphate-buffered 
saline (PBS) and treated with trypsin (0.25% (w/v) trypsin, 0.5 mM EDTA in PBS) at 37°C 
for 3-4 minutes or until cells were dispersed. An appropriate volume of complete growth 
medium was added to block trypsin. The solution of cells were removed from the flask, 
collected in a falcon tube and centrifuged at 800 rpm for 5 minutes. Cell pellet was then 
resuspended in 1 ml new warm medium and an aliquot was collected to count cells in a 
Burker cell counting chamber. Cells were finally plated in a new flask in a proper 
concentration. For sub-cultivation, cells were resuspended in complete growth medium, 
according to the following ratio: 
• MCF7 at a ratio of 1:4; 
• Sk-BR-3 at ratio of 1:2; 
• MDA-MB 231 at ratio of 1:3; 
Cells were frozen at a density of approximately 2 x 106 cells/ml in FBS with 10% DMSO 
(Dimethyl sulfoxide) and then stored at -80°C.  
 
3.6.1 RNA Extraction from Cell Lines 
MCF-7, MDA-MB-231 and SK-BR-3 RNAs were extracted from 2x106 cell pellets with 1 
ml of TRIzol  Reagent (Invitrogen) following the manufacturer’s instruction. In brief, for 
the separation phase, 200 µl of chloroform (Sigma-Aldrich) was added and the tube was 
vortexed for 15 seconds. After an incubation of 3 minutes on ice, samples were centrifuged 
at 12000 x g for 15 minutes at 4°C and the three phases separation was obtained. The upper 
acqueous phase containing the RNA was collected and placed in a new tube. RNA was then 
precipitated with 500 µl of isopropanol. After that, glycogen was added and samples were 
centrifuged at 1200 x g for 10 minutes at 4 °C. The surnatant was removed and the pellet 
  Materials and methods 
41 
 
was washed with 1 ml of cold 70% ethanol. Finally, the RNA pellets were resuspended in 
DEPC treated water, quantified by spectrophotometric reading and stored at -80°C. 
 
3.6.2 DNase Treatment, Reverse Transcription and PCR 
DNase treatment was performed as previously described in paragraph 3.5.2. 
Reverse transcription was performed with SuperScript II TM Reverse Transcriptase 
(Invitrogen) according to manufacture’s instructions. Oligo dT priming (Integrated DNA 
Technologies) was used instead of random hexamers. Briefly, 4.5 µg of total RNA were 
mixed with 1 µl dNTPs (10mM each), l µl oligo dT (0.5 µg/µl) in a final volume of 12 µl. 
The mixture was heated at 65 °C for 5 minutes and rapidly chilled on ice. Later, 8 µl of RT 
mixture were added, yielding a final concentration of 1X First Strand Buffer (50 mM Tris-
HCl pH 8.3; 75 mM KCl; 3 mM MgCl2 - Invitrogen), 10 mM DTT (Invitrogen), 4 units of 
Rnase Inhibitor (Promega) and 200 units of SuperScript TM II RT (Invitrogen) in a final 
volume of 20 µl. The mixture was incubated at 42°C for 1 hour, then the reaction was 
blocked by heat inactivation at 70 °C for 15 minutes. 
Thirty ng of cDNA were used in end-point PCR (Thermal Cycler, Biorad),to set up 
annealing temperature through a thermal gradient program. Each amplification was 
performed in a mixture containing 1X PCR buffer (10 mM Tris-HCl, pH 8.3; 50 mM KCl), 
1.5 mM MgCl2, dNTPs (each 0.2 mM), primers (15 pmol each) and 0.9 units of AmpliTaq® 
Gold DNA Polymerase (Applied Biosystems), in a final volume of 25 µl. PCR program 
was: hot-started at 95°C for 7 minutes, subsequently denaturation for 30 seconds at 95°C, a 
specific gradient temperature for annealing for 1 minutes, extension for 30 seconds at 72°C. 
A program of 35 cycles was used to amplify the targets. Ten µl of each PCR reaction were 
loaded onto 2% agarose gel, stained with ethidium bromide, and visualized under UV 
transilluminator. 
 
3.7 Statistical Analysis 
Associations between clinical-pathological factors and categories of markers were tested for 
significance using the chi-square test (or Fisher’s exact test depending on the sample size) 
for categorical variables. The distribution of data for continuous variables was tested by 
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kurtosis test to establish the statistical tests (parametric or non-parametric) to use. For 
continuous variables normally distributed the parametric Student’s t-test and one-way 
ANOVA test were used. For those variables asymmetrically distributed non parametric 
Kruskal-Wallis test were used. The Spearman’s rank correlation coefficient was used to test 
the strength of correlation for non-parametric variables. For the comparison of 
immunohistochemical markers between primary tumour and paired metastatic lymph node 
the sign test for matched pairs was used. Real time qRT-PCR normalized values for the 
genes were dichotomized for subsequent analysis with respect to their median value of 
expression. Tumours with gene expression levels lower or higher than the median value 
were classified as low or high status of expression, respectively. BC specific survival was 
defined as the time from surgery to breast cancer specific death or end of follow-up, 
whichever came first. The log-rank test and Kaplan-Meier curves were used to estimate and 
compare the dependence of BC patients’ specific survival on single variables or on 
combinations of variables, namely the molecular classification, immunohistochemical 
markers, the expression of genes, the clinical and pathological variables taken one at time. 
To estimate the joint effects of the analysed covariates on patients’ survival and confirm the 
results of the log-rank test, the data were analysed by fitting the Cox proportional hazard 
regression model. The power of the study was calculated by exponential test, which 
compares two exponential survivor functions calculated on the hazard ratio in the groups of 
interest: Ki67 status in luminal patients LN- and LN+, and CK8 expression in loco-regional 
metastasis. 
All p-values are two-sided with values <0.05 regarded as statistically significant, but for 
Kruskal-Wallis test the adjusted significance value was considered for statistics (p<0.05). P-
values between 0.05 and 0.07 were considered “borderline”. 
Statistical analyses were performed with the Stata/SE 12 package (Stata, College Station, 
TX). 
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4 RESULTS 
The first part of the study was related to the molecular characterization of primary tumours 
and a set of metastatic lymph nodes of BC patients with respect to clinical and 
pathological features. The second part dealt with the analysis of 9 genes of interest as 
candidate prognostic biomarker, in association with the molecular classification. 
 
4.1 Description of Clinical and Pathological Features 
The cohort of BC patients included 305 young women with an age at diagnosis less than or 
equal to 55 years 151 patients were negative for axillary loco-regional lymph node 
involvement (LN-), and 154 were positive for axillary loco-regional lymph nodes 
metastases (LN+) at the time of diagnosis (Table 6). The cohort of patients presented an 
average age at diagnosis of 46.9 years (range 26-55). No significant differences in age at 
diagnosis were observed between the LN- (46.8 y, range 32-55 y) and LN+ (47.0 y, range 
26-55 y), but the frequency of patients under 35 was higher in LN+. Fifteen patients (5%) 
were lost at follow-up during the period of observation because of emigration. For those 
the follow-up end at the time of emigration. 
Patients were treated with radical mastectomy, modified radical mastectomy or breast-
conserving surgery, with or without axillary lymph node dissection. All patients submitted 
to conserving surgery were treated with radiotherapy. In detail, in patients LN- or LN+ 
with 3 or less lymph nodes involved, only the breast was irradiated; in patients with more 
than 3 metastatic lymph nodes and capsule invasion, breast and axilla were irradiated. All 
LN+ patients were treated with adjuvant chemotherapy with CMF (cyclophosphamide, 
methotrexate, fluorouracil) or EC/ECF (epirubicin, cyclophosphamide, fluorouracil) 
regimens according to standard protocols. ER-positive patients, both LN- and LN+, were 
submitted to hormone therapy with Tamoxifen. No specific treatment with trastuzumab 
was performed in patients HER2+.  
The mean follow-up time was 14 years (range 0-25), in detail it was 16 years (range 0-25) 
for LN- group and 11 years (range 0-24) for the LN+ group (p<0.001). In the LN- group 
49 women (33%) recurred, while in the LN+ group 98 patients (69%) developed 
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recurrences. For 4 LN- patients (3%) and 11 LN+ ones (7%) information about 
recurrences was missing.  
Significant differences between LN- and LN+ subgroups were detected for frequency of 
women aged less than 35 years at diagnosis (p=0.004), histological subtypes (p=0.001), 
histological grade (p<0.001), tumour size (p<0.001), type of surgery (p<0.001), 
recurrences (p<0.001) and number of patients who died from BC (p<0.001). All details are 
reported in Table 5. 
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Features 
Entire cohort 
N=305 
n (%) 
LN- 
N=151 
n (%) 
LN+  
N=154 
n (%) 
p 
Age, years 
≤35 
>35 
 
21 (7) 
284 (93) 
 
4 (3)  
147 (97) 
 
17 (11)  
137 (89) 
0.004 
Mean Age, years 
(range) 
46.9 
(26-55) 
46.8 
(32-55) 
47.0 
(26-55) 0.2 
Histology 
Ductal 
Lobular 
Medullary 
Mucinous 
Tubular 
 
250 (82) 
28 (9) 
8 (3) 
7 (2) 
12 (4) 
 
115 (76)  
13 (9) 
8 (5) 
4 (3) 
11 (7) 
 
135 (87) 
15 (10) 
0  
3 (2) 
1(1) 
0.001 
Grade 
1 
2 
3 
 
39 (13) 
145 (47) 
121 (40) 
 
34 (22) 
86 (57) 
31 (21) 
 
5 (3) 
59 (38) 
90 (59) 
<0.001 
Tumour size, cm 
≤2 
2-5 
≥5 
Missing 
 
181 (60) 
106 (35) 
15 (5) 
3 
 
109 (72) 
39 (26) 
3 (2) 
0 
 
72 (48) 
67 (44) 
12 (8) 
3 
<0.001 
Lymph nodes 
1-3 lymph nodes 
≥4 lymph nodes 
 
97 (63) 
56 (37) 
 
0 
0 
 
97 (63) 
56 (37) 
 
Stage 
I 
II 
III 
Missing 
 
107 (35)  
125 (41) 
72 (24) 
1 
 
107 (71) 
42 (28) 
2 (1) 
0 
 
0 
83 (54) 
70 (46) 
1 
 
Type of surgery 
Mastectomy 
Breast-
conservation 
 
221 
84 
 
88 
63 
 
133 
21 
<0.001 
Recurrence * 
No 
Yes 
Missing 
 
143 (49)  
147 (51)  
15 
 
98 (67)  
49 (33)  
4 
 
45 (31)  
98 (69)  
11 
<0.001 
BC specific death 128 (42) 39 (26) 89 (58) <0.001 
Table 5. Clinical and pathological characteristics of BC patients. Entire cohort=305, LN-=151, 
LN+=154 (* Recurrences diagnosed during follow-up period; p= level of significance for 
association). 
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4.2 Molecular Classification  
The immunohistochemistry results for ER, PR, HER-2, Ki67, CK8, CK5/6 and vimentin, 
were dichotomized in negative and positive expression for each marker, according to the 
previously described criteria (material and methods section).  
Subsequently, 305 BC patients were molecularly classified into 4 subtypes in agreement 
with their protein expression pattern (paragraph 3.4.3).  
A total of three cases (1%) failed to be classified in one of the molecular subtypes because 
not in line with the previously described criteria. In detail, one case exhibited positive 
staining for PR, CK8, high Ki67, but not ER, HER2 and Ck5/6. The second case showed 
only high positivity for Ki67, but negativity for the other markers (probably it should be 
included in triple negative). The third case exhibited positivity only for CK8. All details 
regarding the staining for the 7 markers are reported in Table 6. 
The remaining 303 cases were classified as follows: luminal A was the most frequent 
molecular subtype with 140 patients (46%), followed by luminal B with 102 cases (34%), 
36 basal-like (12%) and 24 HER-2+ (8%). Results were reported in Table 7 and 8. 
Most cases in luminal A and B showed positive PR expression (96% and 87% 
respectively). Among the luminal subtypes a small percentage of cases (11% and 13% 
respectively for luminal A and B) showed positivity for basal cytokeratins. In the luminal 
B subtype 37 cases (36%) showed HER-2 amplification, of those 4 samples (11%) had a 
Ki67 rate less than 14%, while 33 (89%) cases had a higher Ki67 rate.  
Most HER-2+ (83%) and basal-like (86%) tumours were characterized by high Ki67 
expression (>14%). Moreover, in the HER-2+ subtype a large portion of cases (79%) was 
positive to CK8 and fewer (21%) were positive to CK5/6. Also in basal-like subtype, more 
than half cases showed CK8 positivity (64%). 
Vimentin was prevalently expressed in basal like cases, 75% of positive tumours, in 
comparison to other classes (p<0.001). Luminal A subtype showed the lower rate of 
positivity for vimentin (24%), while luminal B and Her-2 had similar proportion of 
vimentin expression. 
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Fig. 6. Representative picture of immunohistochemistry expression for A: ER, B: PR, C: HER2, D: 
Ki67, E: CK8, F: CK5/6 and G: Vimentin. Pictures are at 20X magnification. 
 
 
Fig. 7. Representative picture of SISH for chromosome 17 (A) and HER-2 (B). 
 
A B C 
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G 
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Marker 
Entire cohort  
N=305 
n (%) 
LN-  
N=151 
n (%) 
LN+ 
N=154 
n (%) 
p 
ER 
Negative 
Positive 
 
63 (21) 
242 (79) 
 
25 (17) 
126 (83) 
 
38 (25) 
116 (75) 
0.08 
PR 
Negative  
Positive 
 
81 (27) 
224 (73) 
 
27 (18) 
124 (82) 
 
54 (35) 
100 (65) 
0.001 
HER-2 
Negative  
Positive 
 
244 (80) 
61 (20) 
 
140 (93) 
11 (7) 
 
104 (67) 
50 (33) 
<0.001 
Ki67 
<14% 
≥14% 
 
156 (51) 
149 (49) 
 
104 (69) 
47 (31) 
 
52 (34) 
102 (66) 
<0.001 
CK8 
Negative 
Positive 
 
29 (10) 
276 (90) 
 
11 (7) 
140 (93) 
 
18 (12) 
136 (88) 
0.3 
CK5/6 
Negative 
Positive 
 
235 (77) 
70 (23) 
 
109 (72) 
42 (28) 
 
126 (82) 
28 (18) 
0.04 
Vimentin 
Negative 
Positive 
 
196 (64) 
109 (36) 
 
106 (70) 
45 (30) 
 
90 (58) 
64 (42) 
0.03 
Table 6. Immunohistochemistry results for the markers used in primary tumours characterization. 
Entire cohort=305, LN-=151, LN+=154 (* Recurrences diagnosed during follow-up period; 
p= level of significance for association). 
 
4.3 Clinical and Pathological Features of Molecular Classes 
The clinical and pathological features stratified per molecular subtypes are shown in Table 
7. Significant associations between molecular classification and clinical-pathological 
features were observed for age at diagnosis with 35 years cut-off  (p=0.031), histological 
type (p<0.001), tumour grade (p<0.001), lymph node involvement (p<0.001), tumour stage 
(p<0.001) and development of later recurrences (p=0.02).  
Patients younger than 35 were related to more aggressive tumours (Soerjomataram et al., 
2008) and were more frequently in luminal B and HER2 subtypes.  
The ductal (NOS) histological type was the most represented in all the classes. Most 
lobular carcinomas were detected in luminal, as well as the less aggressive histological 
types, mucinous and tubular (Ellis et al., 2003). Most medullary carcinomas were grouped 
in basal-like type, while the remaining belong to luminal A type.  
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Tumour differentiation was significantly different among the molecular subtypes, grade 1 
was present only in luminal, especially in luminal A, while grade 3 mostly in HER2 and 
basal like (p<0001).  
Regarding lymph node involvement, luminal A subtype was prevalently associated to 
lymph node negative patients (70%), while the opposite situation occurred for luminal B, 
where 73% of cases presented positive lymph nodes. HER-2+ subtype was more frequent 
in LN+ (79%). The basal-like tumours were equally distributed between LN- and LN+ 
groups. Patients with luminal B and HER-2+ tumours presented more frequently loco-
regional metastases at the diagnosis than patients with luminal A (p<0.001 for both). 
Moreover, HER2+ and basal-like tumours presented a higher number of metastatic lymph 
nodes (≥4), even if the association between molecular subtypes and number of positive 
lymph nodes was not statistically significant. 
Most luminal A tumours were stage I at the diagnosis, while most luminal B were stage II 
and almost half of HER2+ stage III. Basal-like tumours were equally distributed in the 
three stages. Tumour size was not statistically different among molecular subtypes, but it 
was significantly higher in lymph node positive group (p<0.001). Comparing the LN- from 
LN+ groups of patients, we observed for all molecular subtypes a general, non-significant 
trend of higher tumour size (≥5 cm) for patients with positive lymph nodes.  
In the entire case study, luminal A subtype showed the lowest percentage of recurrences, 
while more than 75% of HER-2 tumours relapsed. Luminal B and basal-like showed 
similar intermediate percentage of recurrences. When we analysed LN- and LN+ groups 
separately we observed similar frequency of recurrences for luminal subtypes: 33% and 
26% of recurrences in luminal A and luminal B in LN-; 64% and 67% for luminal A and B 
in LN+ respectively.  
Vimentin expression was prevalently associated to LN+ tumours (p=0.03), higher 
histological grade (p<0.001), tumour stage III (p=0.07) and presence of later recurrences 
(p=0.003) in all the case study. Moreover, the medullary histological type showed the 
highest percentage of vimentin expression (88%), with respect to ductal and lobular (both 
36%), tubular (25%) and mucinous, which showed no expression (p<0.001). 
In addition, almost half of patients (44%) who died from BC were vimentin positive, 
against 29% of positive expression in women who are still alive at the end of follow-up 
(p=0.014). Local or distant recurrences were recorded in 42% of luminal A, 55% of 
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luminal B, 77% of HER-2 and 57% of basal-like tumours. The pattern of metastatic sites 
was reported in Table 8. Organ distribution of metastasis among molecular subtypes was 
almost similar, but for bone and brain. HER-2+ type exhibited a low rate (12%) of bone 
metastasis in comparison to others subtypes (p=0.03), in detail for bone involvement 
significant differences were found between HER2+ and luminal B (p=0.01), and basal-like 
(p=0.04). Higher rate of brain metastases were found in both Her-2+ (17%) and basal-like 
(11%) (p=0.03). In detail, a significant difference for brain metastases was observed 
between HER2+ and luminal A (p=0.02), basal-like and luminal A (p=0.04). 
 
Features 
Luminal A  
N=140 
n (%) 
Luminal B  
N=102 
n (%) 
HER-2 
N=24 
n (%) 
Basal-like 
N=36 
n (%) 
p 
Age (years) 
≤35 
>35 
 
4 (3) 
136 (97) 
 
10 (10) 
92 (90) 
 
4 (17) 
20 (83) 
 
2 (6) 
34 (94) 
0.03 
Age (years) 
range 
47.4 
30-55 
46.6 
30-55 
45.9 
28-55 
47.0 
34-55 0.7 
Histology 
Ductal 
Lobular 
Medullary 
Mucinous 
Tubular 
 
108 (77) 
16 (12) 
2 (1) 
3 (2) 
11 (8) 
 
88 (86) 
10 (10) 
0 
3 (3) 
1 (1) 
 
23 (96) 
1 (4) 
0 
0 
0 
 
28 (78) 
 1 (3) 
6 (16) 
1 (3) 
0 
<0.001 
Grade 
1 
2 
3 
 
34 (25) 
77 (55) 
29 (20) 
 
5 (4) 
49 (48) 
48 (48) 
 
0 
9 (37) 
15 (63) 
 
0 
9 (25) 
27 (75) 
<0.001 
Tumour 
size(cm) 
≤2 
2-5 
≥5 
Missing 
 
 
95 (68) 
39 (28) 
5 (4) 
1 
 
 
50 (49) 
44 (43) 
7 (7) 
1 
 
 
12 (50) 
11 (46) 
1 (4) 
0 
 
 
22 (63) 
11 (31) 
2 (6) 
1 
0.1 
Lymp node 
involvement 
no 
yes 
 
 
98 (70) 
42 (30) 
 
 
28(27) 
74 (73) 
 
 
5 (21) 
19 (79) 
 
 
18 (50) 
18 (50) 
<0.001 
Lymph nodes 
1-3  
≥4  
Missing 
 
28 (67) 
14 (33) 
0 
 
51 (69) 
23 (31) 
0 
 
10 (53) 
9 (47) 
0 
 
7 (39) 
10 (56) 
 1 
0.1 
Stage 
I 
II 
III 
Missing 
 
71 (51) 
48 (34) 
21 (15) 
0 
 
17 (16) 
55 (54) 
30 (30) 
0 
 
4 (16) 
9 (38) 
11 (46) 
0 
 
13 (37) 
12 (34) 
10 (29) 
1 
<0.001 
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Recurrence 
No 
Yes 
Missing 
 
78 (58) 
56 (42) 
6 
 
43 (45) 
53 (55) 
6 
 
5 (23) 
17 (77) 
2 
 
15 (43) 
20 (57) 
1 
0.02 
Status 
BC specific death 
 
45 (32) 
 
48 (47) 
 
14 (58) 
 
19 (53) 0.001 
ER 
Negative 
Positive 
 
0 
140 (100) 
 
0 
102 (100) 
 
24 (100) 
0 
 
36 (100) 
0 
<0.001 
PR 
Negative  
Positive 
 
6 (4) 
134 (96) 
 
13 (13) 
89 (87) 
 
24 (100) 
0 
 
36 (100) 
0 
<0.001 
HER-2 
Negative  
Positive 
 
140 (100) 
0 
 
65 (64) 
37 (36) 
 
0 
24 (100) 
 
36 (100) 
0 
<0.001 
Ki67 
<14% 
≥14% 
 
140 (100) 
0 
 
6 (6) 
96 (94) 
 
4 (17)  
20 (83) 
 
5 (14) 
31 (86) 
<0.001 
CK8 
Negative 
Positive 
 
0 
140 (100) 
 
0 
102 (100) 
 
5 (21) 
19 (79) 
 
23 (64) 
13 (36) 
<0.001 
CK5/6 
Negative 
Positive 
 
125 (89) 
15 (11) 
 
89 (87) 
13 (13) 
 
19 (79) 
5 (21) 
 
0 
36 (100) 
<0.001 
Vimentin 
Negative 
Positive 
 
107 (76) 
33 (24) 
 
65 (64) 
37 (36) 
 
14 (58) 
10 (42) 
 
9 (25) 
27 (75) 
<0.001 
Table 7. General clinical-pathological and IHC characteristics of breast tumours according to 
molecular classification. Luminal A= 140, Luminal B=102, HER-2+= 24, Basal-like= 36. (p= 
level of significance for association). 
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Metastatic site Luminal A  
n (%) 
Luminal B  
n (%) 
HER-2  
n (%) 
Basal-like  
n (%) 
p 
Bone 22 (16) 29 (28) 3 (12) 11 (31) 0.03 
Liver 27 (19) 27 (26) 7 (29) 12 (33) 0.7 
Lung and Pleura 24 (17) 20 (20) 6 (25) 13 (36) 0.2 
Brain 2 (1) 8 (8) 4 (17) 4 (11) 0.03 
Endocrine * 4 (3) 4 (4) 1 (4) 1 (3) 0.9 
Distant LN ** 4 (3) 2 (2) 1 (4) 1 (3) 0.9 
Other *** 5 (4) 6 (6) 1 (4) 1 (3) 0.9 
Local 22 (16) 13 (13) 7 (29) 5 (14) 0.3 
Table 8. Metastasis sites and local recurrence in accordance to BC molecular subtypes over the 
patients who recurred (N=146). * Endocrine sites include thyroid, ovary and kidney. ** 
Distant lymph nodes are considered the nodes that do not belong to the axilla, including the 
supraclavicular lymph nodes. *** Other sites comprise peritoneum and pericardium. (p= 
level of significance for association). 
 
4.4 Survival Analysis 
4.4.1  Role of Clinical and Pathological Features 
At the end of the follow-up 128 women died of BC, 16 died of any cause unrelated to BC, 
18 were lost at follow-up, because of emigration, and 143 patients were alive. In the LN- 
group 7 women (5%) died from causes different from BC and 39 patients (26%) died of 
breast cancer specific-death. Within the LN+ group 9 women (6%) had a non-BC-specific 
death, while 89 patients (58%) died from BC. 
Log-rank test for clinical and pathological variables among the entire cohort of patients 
revealed that histological type of tumour (p=0.04) (Fig. 8A), histological grade (p<0.001) 
(Fig. 8B), tumour size (p=0.02) (Fig. 8C), lymph node involvement (p<0.001) (Fig. 8D), 
number of positive lymph nodes (p=0.01) (Fig. 8E) and stage of tumour (p<0.001) (Fig. 
8F) were significant for BC specific survival. Age at diagnosis was not significant (p=0.1). 
Also the presence of later recurrences negatively affected BC specific survival (p<0.001). 
In detail patients with negative nodes, mucinous and tubular histological type, tumour size 
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less than 2 cm, a number of positive lymph nodes equal or less than 3, with tumour stage I 
and well differentiated tumour (G1-G2) showed a significant higher BC specific survival. 
The Cox proportional hazard model was performed for histological type of tumour, tumour 
grade, tumour size, lymph node status and age at diagnosis. It emerged that histological 
type of tumour played a protective role on patient’s survival (hazard ratio 0.8, p=0.04), 
tumour grade affected negatively BC specific survival (hazard ratio 1.5, p=0.006) and also 
lymph node involvement constituted a higher risk for BC death (hazard ratio 2.2, p<0.001) 
(probability of the model p<0.001). 
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Fig. 8. Kaplan-Meyer survival curves for the entire cohort (N=305, 128 BC specific deaths) over the 
following clinical and pathological features: histological type of tumour (A), histological 
tumour grade (B), tumour size (C), lymph node involvement (D), number of positive nodes 
among LN+ patients (E), tumour stage (F). 
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4.4.2 Role of Molecular Classification 
BC specific survival curves for molecular classes in the entire cohort of patients are shown 
in Fig. 9A and the corresponding survival estimates are listed in Table 9. A significant 
better BC specific survival was recorded for luminal A tumours and a worse outcome for 
HER-2 subtype (p=0.0003). In detail, significant differences were found between luminal 
A and luminal B (p=0.009), luminal A and HER-2+ (p<0.001), luminal A and basal-like 
(p=0.01), luminal B and HER-2+ (p=0.04). No significant differences between HER-2+ 
and basal like (p=0.3), luminal B and basal-like (p=0.5) were detected. 
Furthermore, all patients with HER-2+ tumours showed a early BC specific death within 5 
years, except for one patient. In addition, women with basal-like subtype died from BC 
within 10 years, only one woman died at 13 years of follow-up. Women who had luminal 
tumours continued to die from BC even after 20 years of follow-up, with a constant 
reduction of survival estimates. 
When we separately analysed BC specific survival in the groups of LN- and LN+ patients, 
a statistically significant difference among molecular classes was no longer observed 
(p=0.09 and p=0.2 for LN- and LN+), as shown in Fig 9B-C. Luminal A and luminal B 
subtypes displayed similar survival in LN- and LN+ subgroups respectively, showing that 
differences between A and B subgroups are likely related not to molecular subtypes, but to 
differentiation and stage at the diagnosis, which were higher in most luminal B cases. 
Luminal A and luminal B classes showed a significant better survival in LN- in 
comparison to LN+ (p<0.001 and p=0.001, respectively). On the other hand, both HER-2 
and basal-like subtypes did not show statistically significant differences for survival over 
lymph node stratification (p=0.2 for both). 
Moreover, luminal tumours expressing PR showed a better outcome in comparison to 
those lacking its expression (p=0.02) (Fig. 10A), in particular in luminal A tumours 
(p=0.03) (Fig. 10B). In luminal B neither the expression of PR (p=0.3) or HER-2 (p=0.5) 
resulted significantly associated to BC specific survival. The expression of Ck5/6 in 
luminal tumours was not related to the patients’ outcome (p=1.0 and p=0.8 for luminal A 
and luminal B, respectively). 
In HER-2+ and basal-like subtypes Ki67 did not affect significantly BC specific patients’ 
survival (p=0.5 and p=0.4, respectively). 
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A separate mention was dedicated to vimentin, since it was not involved in molecular 
classes definition. The log-rank test revealed that positive vimentin expression was 
associated to shorter BC specific survival in the entire cohort of patients (p=0.009) and in 
LN- group (p=0.02), but not in LN+ patients (p=0.6). Stratifying patients into the four 
molecular classes, the logrank test showed shorter survival in luminal (p=0.03) and 
luminal B patients (p=0.04) for positive vimentin expression, as showed in Fig. 10 C-D. 
This marker was not significant for BC specific survival in the others molecular classes 
(p=0.5, p=0.9, p=0.6 respectively for luminal A, HER-2+ and basal-like).  
Multivariate Cox regression model was run for the pathological covariates lymph node 
involvement, tumour size, histological type, histological grade, age at diagnosis and the 
molecular classes. The analysis revealed that lymph node involvement (p<0.001) and 
histological grade (p=0.05) were significant prognostic factor for worse outcome. Instead, 
histological type (p=0.04), luminal A (p=0.04) and luminal B (p=0.03) remained a 
significant prognostic factor for good patients’ outcome, as reported in table 10.  
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Time Luminal A (%) (95% CI) 
Luminal B 
(%) (95% CI) 
HER2 
(%) (95% CI) 
Basal-like 
(%) (95% CI) 
5-year 87 (80-91%) 85 (76-90%) 44 (24-63%) 58 (40-72%) 
10-year 75 (67-81%) 66 (55-74%) 44 (24-63%) 49 (32-64%) 
15-year 72 (64-79%) 56 (46-66%) 44 (24-63%) 46 (29-62%) 
20-year 67 (58-74%) 48 (36-59%) 35 (15-57%) 46 (29-62%) 
25-year 65 (56-73%) 46 (35-57%) - 46 (29-62%) 
Part I 
Time Luminal A (%) (95% CI) 
Luminal B 
(%) (95% CI) 
HER2 
(%) (95% CI) 
Basal-like 
(%) (95% CI) 
5-year 92 (84-96%) 96 (75-99%) 60 (13-88%) 72 (46-87%) 
10-year 85 (76-90%) 96 (75-99%) 60 (13-88%) 61 (35-79%) 
15-year 81 (71-87%) 85 (64-94%) 60 (13-88%) 56 (31-75%) 
20-year 78 (68-85%) 75 (52-88%) 60 (13-88%) 56 (31-75%) 
25-year 75 (64-83%) 75 (52-88%) - 56 (31-75%) 
Part II 
Time Luminal A (%) (95% CI) 
Luminal B 
(%) (95% CI) 
HER2 
(%) (95% CI) 
Basal-like 
(%) (95% CI) 
5-year 76 (60-86%) 80 (69-88%) 40 (18-61%) 43 (20-64%) 
10-year 52 (36-66%) 54 (42-65%) 40 (18-61%) 37 (15-58%) 
15-year 52 (36-66%) 45 (33-57%) 40 (18-61%) 37 (15-58%) 
20-year 42 (26-58%) 38 (26-50%) 27 (6-54%) 37 (15-58%) 
25-year - - - - 
Part III 
Table 9. BC specific survival estimates by molecular classes in the entire cohort (part I) (N=303), in 
LN- group (N=149) (part II) and LN+ group (N=153) (part III). (CI= Confidence Interval). 
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Fig. 9. Kaplan-Meier survival curves with respect to molecular classes in the cohort of BC patients 
(A) (N=303, 126 BC specific deaths), lymph node negative tumours (B) (N=149, 38 BC specific 
deaths), classes in lymph node positive tumours (C) (N=153, 88 BC specific deaths). 
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Fig. 10. Kaplan-Meyer survival curves according to PR and vimentin expression in patients classified 
as ‘luminal’. Survival by PR in all luminal tumours (A) (N=242, 93 BC specific deaths) and in 
luminal A tumours (B) (N=140, 45 BC specific deaths). Survival by vimentin in all luminal 
tumours (C) and in luminal B tumours (B). 
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Risk Factors Hazard Ratio 95% CI* p 
Age at diagnosis 1.0 0.9-1.0 0.4 
Histologic type 0.8 0.6-1.0 0.04 
Grade 1.4 1.0-1.9 0.05 
Tumour size 1.2 0.9-1.7 0.2 
Lymph node 2.4 1.5-3.7 0.000 
Luminal A 0.2 0.1-0.9 0.04 
Luminal B 0.2 0.1-0.8 0.03 
HER-2+ 0.3 0.1-1.4 0.1 
Basal-like 0.4 1.0-1.6 0.2 
Table 10. Results of Cox proportional hazard model of BC specific survival (N=303, 128 BC specific 
deaths) (*Confidence Interval, p= level of significance for association). 
 
4.4.3 Luminal Tumours 
The long follow-up period allowed us to observe that the ER-positive patients showed the 
presence of very long-term recurrences, contrary to ER-negative tumours. For this reason, 
we focused on luminal A and luminal B tumours and we compared patients who had 
‘early’ and ‘late’ BC specific death. We considered as ‘early’ BC specific deaths those 
occurred within 5 years, ‘intermediate’ the one between 6 and 10 years of follow-up, ‘late’ 
BC specific deaths those that happened after 10 years of follow-up. Among the 93 patients 
with luminal tumours, who died from BC, 33 (35%) women had ‘early’ BC specific death, 
35 (38%) patients died from BC between 6-10 years of follow-up, and 25 (27%) patients 
had a “late” one. 
The Log-rank test was used to test the influence of the pathological features and markers 
among the ‘early’, the ‘intermediate’ and the ‘late’ groups of BC specific death, 
separately. All details are reported in Table 11. 
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• In patients who had ‘early’ BC death, histological type of tumour (p=0.3), and age at 
diagnosis (35 years cut-off) (p=0.9) did not significantly affect BC patients’ survival. 
Otherwise, tumour grade (p<0.001), tumour size (p=0.006), lymph node involvement 
(p<0.001) number of positive nodes (p=0.02) and tumour stage (p<0.001) resulted 
significant for BC specific survival. In detail, tumour with G3 histologic grade, size 
larger than 2 cm, more than 3 positive lymph nodes involved at diagnosis and stage III 
are more likely to cause a BC specific death within 5 years. BC specific deaths were 
not significantly different between luminal A and B (p=0.6). PR negative patients 
showed a worse survival within 5 year (p=0.06) with respect to positive ones. No 
significant influence on BC survival was detected for HER-2 (p=0.6), Ck5/6 (p=0.4) 
and vimentin (p=0.3). 
• In the ‘intermediate group’, clinical parameters with significant influence on survival 
were: histologic grade (p=0.01) lymph node involvement (p<0.0001), tumour size 
(p=0.03) and tumour stage (p<0.001). In detail, tumour of grade 3, larger than 2 cm, 
LN+, showed a worse BC survival in this period of time. Conversely, histological type 
of tumour (p=0.9), number of positive lymph nodes (p=0.8), age at diagnosis (p=0.9), 
type of luminal (p=0.1) did not affect BC specific survival. Moreover, PR negative 
patients had shorter BC survival (p=0.06). HER2, CK5/6 and vimentin expression did 
not affect patient’s survival (p=0.4, p=0.8, p=0.08 respectively). 
• Histological type (p=0.4), histologic grade (p=0.1), number of positive lymph nodes 
(p=0.8) did not significantly affect ‘late’ BC specific death. Tumour size did not result 
significant, although small tumours (size ≤2 cm) tended to have late BC specific death 
with 19 dead patients out of 25 (76%). Tumour stage also showed a similar trend, with 
9 out of 25 patients (36%) of stage I who died from BC after 10 years (p=0.3). 
Tumour size and histologic grade showed an inversion in comparison to the results 
obtained within 5 years of follow-up. Only lymph node involvement was statistically 
significant (p=0.04). Patients with positive lymph nodes (73%) are more likely to have 
early BC specific death with respect to ‘late’ one (52%). Finally, patients with luminal 
B tumours tend to have more frequently ‘late’ BC specific death than luminal A 
(p=0.01). The role of HER-2 and vimentin expression showed a border influence on 
BC survival, tumours overexpressing HER-2 and positive for vimentin had a shorter 
survival (p=0.08 both). CK5/6 expression did not affect ‘late’ BC death (p=0.8). 
 
 
  Results 
62 
 
Features 
Early BC death 
N=33 
n (%) 
Intermediate BC death  
N=35 
n (%) 
Late BC death 
N=25 
n (%) 
Age (years) 
≤35 
>35 
 
2 (6) 
31 (94) 
 
2 (6) 
33 (94) 
 
1 (4) 
24 (96) 
Histology 
Ductal 
Lobular 
Medullary 
 
31 (94) 
2 (6) 
0 
 
31 (89) 
4 (11) 
0 
 
19 (76) 
5 (20) 
1 (4) 
Grade 
1 
2 
3 
 
0 
14 (42) 
19 (58) 
 
1 (3) 
20 (57) 
14 (40) 
 
2 (8) 
17 (68) 
6 (24) 
Tumour size (cm) 
≤2 
2-5 
≥5 
Missing 
 
13 (39) 
16 (48) 
4 (12) 
0 
 
15 (45) 
16 (48) 
2 (6) 
2 
 
19 (76) 
6 (24) 
0 
0 
Lymph node involvement 
no 
yes 
 
9 (27) 
24 (73) 
 
7 (20) 
28 (80) 
 
12 (48) 
13 (52) 
Lymph nodes 
1-3  
≥4 
 
12 (50) 
12 (50) 
 
20 (71) 
8 (29) 
 
9 (69) 
4 (31) 
Stage 
I 
II 
III 
 
4 (12) 
13 (39) 
16 (48) 
 
5 (14) 
18 (51) 
12  (34) 
 
9 (36) 
11 (44) 
5 (20) 
PR 
Negative  
Positive 
 
5 (15) 
28 (85) 
 
4 (11) 
31 (89) 
 
1 (4) 
24 (96) 
HER-2 
Negative  
Positive 
 
29(88) 
4 (12) 
 
29 (83) 
6 (17) 
 
19 (76) 
6 (24) 
CK5/6 
Negative 
Positive 
 
31 (94) 
2 (6) 
 
30 (86) 
5 (14) 
 
22 (88) 
3 (12) 
Vimentin 
Negative 
Positive 
 
22 (67) 
11 (33) 
 
21 (60) 
14 (40) 
 
16 (64) 
9 (36) 
Luminal A 
Luminal B 
18 (55) 
15 (45) 
17 (49) 
18 (51) 
10 (40) 
15 (60) 
Table 11. General clinical-pathological and IHC characteristics of luminal A and luminal B patients 
who died from BC subdivided in ‘early’ (BC death within 5 years) ‘intermediate’ (BC death 
between 6-10 years) and ‘late’ (BC after 10 years). 
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4.4.4 Role of Ki67 among Luminal Tumours 
As the subdivision between luminal A and B is based on the count of Ki67 positive nuclei 
(14% cut-off), in case of no HER-2 overexpression, we deepened the distribution of Ki67 
with respect to BC specific survival, especially in luminal tumours. Considering the rate of 
positive Ki67 nuclei as a continuous variable, we investigated the relationship between 
Ki67 percentage and BC specific survival. Ki67 resulted significantly higher in all LN+ 
patients (p<0.001) and in LN+ luminal patients (p<0.001). Nevertheless Ki67 was not able 
to predict the outcome in luminal tumours. Analysing Ki67 percentage separately in LN- 
and LN+ patients, there were not significant differences in Ki67 positivity between living 
and BC dead patients in luminal cancers (p=0.08 in LN- and p= 0.4 in LN+). It seems that 
survival in luminal patients was not affected by Ki67 percentage of positive nuclei, neither 
in LN- negative (p= 0.5), nor in LN+ patients (p= 0.9). This data were also confirmed in 
the solely luminal B group of patients. The distribution of cases by Ki67 in comparison to 
BC specific death showed a continuous increment without apparent cut-off levels (Tab. 
12).  
However, using the Ki67 14% cut-off the Log-rank test revealed as expected a significant 
longer survival for luminal patients with Ki67<14% (p=0.008) (Fig. 11). 
 
Ki67 
percentage 
Cases 
n (%) 
Specific BC deaths 
n (%) 
<5% 58 (24) 12 (21) 
6-10% 43 (19) 16 (37) 
11-13% 43 (19) 18 (42) 
14-20% 33 (14) 14 (42) 
>20% 65 (27) 33 (51) 
Tot 242 93 (38) 
Table 12. Ki67 percentage of positive nuclei in comparison with BC specific death in luminal patients 
classified as luminal 
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Stratifying Ki67 percentage into three categories: ≤10%, 11-20% and > 20%, we found a 
significant p value (p=0.003) for BC specific survival respect to the 14% cut-off (p=0.008) 
as well. The corresponding Kaplan-Meyer curves are reported in Fig. 11A and B. Fig. 11A 
shows that at 4 years of follow-up the curve for 0-10% Ki67 is well separated from the one 
for 11-20%, with a corresponding better survival. Conversely, in Fig. 11B the separation 
for good and worse survival according to the 14% Ki67 cut-off is shifted over 7 years of 
follow-up. 
To further investigate the role of Ki67 and other markers in luminal group tumours, we 
performed the Cox multivariate analysis in luminal tumours, which considered the 
clinical-pathological variables and the molecular markers PR, Ki67, HER-2 and vimentin. 
Neither the percentage rate of Ki67, nor the positivity to PR and HER-2 affected the 
survival of luminal patients, but the histological type (p=0.004), the tumour grade 
(p=0.01), the tumour size (p=0.07) and the involvement of the lymph node at the diagnosis 
(p=0.001) were significant. In Table 13 are reported the results of Cox analysis in luminal 
tumours. 
 
  
Fig. 11. Kaplan-Meyer survival curves for Ki67 percentage of positive cells in luminal tumours 
(N=242, 93 BC specific deaths). Ki67 rate is categorized into three ranges (ki67 ≤10%; 11-
20%; >20%) (A), Ki67 is dichotomized according to the 14% cut-off (B). 
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Risk Factors Hazard Ratio 95% CI Probability 
Age at diagnosis 1.0 1.0-1.1 0.2 
Histological Type 0.7 1.5-4.2 0.04 
Grade 1.5 1.1-2.2 0.01 
Tumour size 1.4 1.0-2.0 0.07 
Lymph node 2.5 1.5-4.2 0.001 
PR 0.9 0.4-1.9 0.7 
Ki67 1.0 1.0-1.1 0.9 
HER-2 0.7 0.4-1.1 0.1 
Vimentin 1.2 0.9-1.0 0.9 
Table 13. Results of Cox proportional hazard model of BC specific survival on patients with luminal 
tumours (N=242, 93 BC specific deaths) (*Confidence Interval, p= level of significance for 
association).  
 
4.5 Molecular Classification in Loco-Regional Metastasis 
In order to investigate the behaviour of molecular classes with respect to the cells which 
colonise the metastatic lymph nodes, we compared the staining of the markers assessed in 
primary tumours to the corresponding metastatic lymph nodes in a set of 100 LN+ 
patients. 
Immunohistochemical assays were performed for ER, PR, HER-2, Ki67, CK8, CK5/6 and 
vimentin using the same conditions and procedures of the primary tumours. The evaluation 
of the staining of each marker was already described in paragraph 3.4.3. 
Five out of 7 markers resulted significantly different between primary tumour and the 
corresponding loco regional metastasis (Table 14). Since some molecular classifiers were 
lost and others acquired at the level of metastatic lymph nodes, the molecular classification 
resulted quite difficult in the latter.  
The expression of each marker was compared in primary tumour and matched metastatic 
lymph node. In detail, ER and PR showed similar rate of positive cases in primary tumour 
and in the corresponding lymph node (p=0.1 and p=0.3 respectively). Nevertheless, the 
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ttest for matched pairs revealed significant differences in the mean percentage of positive 
nuclei for ER (54% and 65% in primary tumour and metastasis, p=0.0003) and PR (40% 
and 53% in primary tumour and metastasis, respectively, p=0.0001). Conversely, 
significant differences were observed for HER-2 (p=0.03), Ki67 (p<0.001), CK8 
(p<0.001), CK5/6 (p<0.001) and vimentin (p=0.04). HER-2 resulted more expressed in 
primary tumour (34%) in comparison to metastatic nodes (23%). Similarly, higher rate of 
Ki67 (Ki67>14%) was observed in primary tumours (66%) compared to metastatic nodes 
(40%). Moreover, the mean percentage of Ki67 positive nuclei in primary tumour was 
25% and in metastatic lymph node it was 17% (p=0.003). CK8 also decreased in the 
metastatic lymph node (58%) with respect to primary tumour (89%). Vimentin expression 
was higher in primary tumour (55%) versus corresponding metastatic nodes (45%), CK5/6 
showed a significant increment of positive cells in metastasis (47%) with respect to 
primary tumour (19%).  
The following results were recorded: 
Luminal A 
Among 28 cases of primary tumour classified as luminal A, 18 (64%) resulted luminal A 
also in the lymph node (ER+ and /or PR+, Ki67<14%, HER-2-); 8 (29%) cases passed to 
luminal B (ER+ and or PR+, Ki67≥14% or ER+ and/or PR+, HER-2+), 1 (4%) acquired 
basal-like phenotype at the lymph node level (ER-, PR-, HER-2-, Ck5/6+) and 1 case 
resulted unclassifiable because it was negative for all the marker except PR.  
Among 28 cases of primary luminal A tumours, in the corresponding metastatic nodes 15 
(54%) cases lost CK8 expression and 11 (39%) cases gained Ck5/6 expression. Nine cases 
(32%) of lymph nodes showed Ki67>14% with respect to the corresponding primary 
tumour. Eleven (39%) primary tumours were vimentin positive, but only 7 metastatic 
lymph nodes  (25%). 
Luminal B 
45 primary tumours were luminal B. The immunostaining results in the corresponding 
metastatic nodes revealed that 24 (53%) lymph nodes remained luminal B (ER+ and or 
PR+, Ki67≥14% or ER+ and/or PR+, HER-2+), while 21 (47%) were classified as luminal 
A (ER+ and /or PR+, Ki67<14%, HER-2-).  
Among the 45 luminal B primary tumours, 30 (67%) cases lost Ck8 expression in the 
corresponding regional metastatic node, while 15 (33%) cases acquired the CK5/6 
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positivity. In addition, 11 (44%) metastatic lymph nodes lost HER-2 overexpression. 43 
cases (96%) showed Ki67>14% in primary tumours, while only 17 cases (38%) in 
metastatic nodes. Vimentin was expressed in 19 (45%) primary tumour and 10 (22%) 
corresponding regional metastasis. 
HER-2+ 
Among 14 cases of HER-2+ primary tumour, 8 (57%) cases remained HER-2, 2 (14%) 
cases switched to basal-like subtype in the lymph node (ER-, PR-, HER-2-, Ck5/6+) and 4 
(29%) cases became luminal B (ER+ and/or PR+, HER-2+).  
Two cases (14%) lost the positivity for HER-2 expression. Overall 4 (29%) cases acquired 
the ER expression and 3 (21%) the PR positivity. HER-2+ primary tumours were all 
positive for CK8, except 1 case, while in the relative metastatic lymph nodes 6 (43%) lost 
the CK8 positivity. A similar result was observed for CK5/6 staining, with only one 
positive case in primary tumours and 6 (29%) cases in the corresponding metastasis. 3 
cases (21%) showed Ki67<14%, while 9 cases (64%) in metastatic lymph nodes. Vimentin 
expression was comparable with 6 cases in primary tumour and 5 in corresponding 
metastasis. 
Basal-like 
Of 13 cases of primary basal-like tumours 6 (46%) cases remained basal at the lymph node 
level, while 2 (15%) cases lost Ck5/6 expression and for this reason they can be classified 
as triple negative (ER-, PR-, HER-2-). Considering together basal-like and TN, 61% of 
regional metastatic nodes remained of the same molecular class as primary tumour. One 
(8%) case changed its phenotype from basal-like to HER-2+ subtype. Other 2 (15%) cases 
resulted not classifiable (PR+, ER-, HER-2+, CK5/6+, CK8- and PR+, ER-, HER-2-, 
CK5/6+ and CK8-). Finally 2 (15%) cases switched to luminal B subtype (ER+ and or 
PR+, Ki67≥14%). 
Overall 3 (23%) cases have lost the positivity for the basal cytokeratin 5/6, while no 
differences were observed for Ck8 expression. Two (13%) cases acquired the positivity for 
HER-2+ expression and 4 (31%) the positivity for PR. Ki67<14% was observed in, 1 case 
(8%) of primary tumour versus 4 (31%) cases of metastatic nodes. Vimentin was 
expressed in 8 cases both in primary tumour and corresponding metastasis and in 1 patient 
the expression was lost in the lymph node. 
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Most specimens preserved their molecular phenotype in the corresponding metastatic 
regional node: 64% for luminal A, 53% for luminal B, 57% for HER-2+ and 61% for 
basal-like tumours. Therefore, relevant changes were detected for single markers, 
generally the acquisition of basal characteristics (CK5/6+) and the loss of the luminal 
(CK8-) features in the metastatic lymph nodes were observed. 
 
Marker Primary Tumour N=100 
Metastatic lymph node 
N=100 p 
ER 
negative 
positive 
 
27% 
73% 
 
23% 
77% 
 
0.1 
PR 
negative 
positive 
 
39% 
61% 
 
31% 
69% 
 
0.3 
HER-2 
negative 
positive 
 
66% 
34% 
 
77% 
23% 
 
0.03 
Ki67 
<14% 
≥14% 
 
34% 
66% 
 
60% 
40% 
 
<0.001 
CK8 
negative 
positive 
 
11% 
89% 
 
42% 
58% 
 
<0.001 
CK5/6 
negative 
positive 
 
81% 
19% 
 
53% 
47% 
 
<0.001 
Vimentin 
negative 
positive 
 
55% 
45% 
 
70% 
30% 
 
0.04 
Table 14.  Comparison of immunohistochemistry results for the seven markers between primary 
tumour and corresponding metastatic lymph node (N=100). (p= level of significance for 
association). 
 
4.5.1 Relationship of Markers with Clinical and Pathological features 
The relationship between markers expression and clinical pathological features was 
evaluated for both primary tumours and corresponding metastatic nodes. The clinical-
pathological parameters analysed were: histologic grade, size of tumour, number of lymph 
nodes involved, tumour stage, histologic type of tumour, presence of later recurrences. 
Only the significant associations are here reported. 
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Primary tumours lacking of ER and PR expression were significantly associated to higher 
histological tumour grade, with respectively 81% and 69% of G3 for ER- and PR- 
(p=0.002 for ER, p=0.06 for PR). The same result was also observed for ER and PR 
assessed in the metastatic lymph node (p=0.002). HER-2 (p=0.04) and Ki67 (p=0.02) 
positivity in primary tumours were mainly associated to less differentiated lesions (71% 
and 65% for HER-2+ and Ki67+). The same was observed for HER-2 in the metastatic 
lesions (p=0.001), with 87% of G3 tumours expressing HER-2 versus 47% of the same 
histological grade but HER-2 negative. For tumour size we did not find any significant 
relationship. 
Moreover, ER expression in primary tumours was significantly associated to the number 
of positive lymph nodes involved (p=0.06). Indeed, 66% of tumours lacking of ER 
expression showed more than 3 positive axillary nodes at diagnosis, with respect to 45% of 
positive ER tumour with more than 3 positive nodes. A similar result was also observed 
for PR: the lack of PR expression was associated to the higher number of metastatic lymph 
nodes at diagnosis, even if the data was not statistically significant (p=0.09). Interestingly, 
HER-2 positive expression assessed in the loco-regional metastasis was found marginally 
associated to the higher number of positive nodes (p=0.06), but nor the expression 
evaluated in the primary tumour. 
For what concerns tumour stage, we observed that PR negative expression was associated 
to higher tumour stage: 69% of stage III had PR-, while 49% of same stage had PR+ 
(p=0.05). The relationship between histologic type of tumours and markers expression 
revealed that vimentin was significantly higher expressed in ductal type with 82% of 
cases, the remnant was found in lobular type, while the tumours classified as mucinous 
were vimentin negative (p=0.02). Furthermore, all loco-regional metastasis coming from 
lobular tumours were negative for HER-2 (p=0.009). Finally we detected a significant 
association between CK8 expression assessed in the metastatic nodes and presence of later 
recurrences (p=0.03). 
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4.6 Survival Analysis for Markers in Metastatic Lymph Node 
Log-rank test revealed that CK8 was the only marker significantly associated to BC 
specific survival: a high expression of CK8 in metastatic lymph nodes was associated to a 
longer survival (p<0.001) in the group of examined LN+ patients, as reported in Fig. 12A.  
Among 100 patients with positive regional lymph nodes, 60 women died from BC, of 
those 27 (45%) showed a positive CK8 expression, while 33 (55%) were negative. 
Contrarily, CK8 positivity in the primary tumours did not affect significantly BC specific 
survival (p=0.9) (Fig. 12B). 
The Cox regression analysis confirmed the CK8 result obtained in univariate survival 
analysis. Namely, the multivariate survival analysis was run for the following variables: 
histological type, tumour grade, tumour size, number of positive lymph nodes and CK8 
expression in metastatic nodes. The number of positive lymph nodes showed a significant 
worse effect on survival (p=0.04), while CK8 expression had protective effect (p<0.001), 
as shown in table 15. We obtained a power of the study equal to 0.9985, using a sample 
number of 100 patients, a significance of 0.05 and two-sided test. 
 
  
Fig. 12. Kaplan-Meyer survival curves with respect to CK8 expression evaluated by means of IHC in 
metastatic lymph nodes (A) and in corresponding primary tumour (B) (N=100, 60 BC specific 
deaths).  
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Risk Factors Hazard Ratio 95% CI* p 
Age at diagnosis 1.0 1.0-1.1 0.3 
Histologic type 0.7 0.5-1.1 0.2 
Grade 1.0 9.6-1.7 0.9 
Tumour size 0.9 0.5-1.4 0.5 
Number of positive nodes 1.9 1.0-3.3 0.04 
CK8 in metastatic nodes 0.4 0.2-0.6 0.0000 
Table 15. Results of Cox proportional hazard model of BC specific survival in the group of LN+ 
patients (N=100, 60 BC specific deaths) (*Confidence Interval, p= level of significance for 
association).  
 
4.7 Gene Expression and Relationship with Clinical and Pathological Features 
The expression of the nine genes, was investigated in relation to the following BC clinical-
pathological factors: histological type (ductal, lobular, medullary, mucinous and tubular), 
tumour grade (1, 2, 3), tumour size (smaller than 2 cm, between 2 and 5 cm, larger than 5 
cm), lymph node involvement (no or yes), number of positive nodes (less or more than 3 
lymph nodes) tumour stage (I, II, III), presence of later recurrence (no or yes), age at 
diagnosis (younger or older than 35 years) and patient status at the end of follow-up (alive 
or dead from BC). 
4.7.1 RB and CDK2 
RB was slightly higher in lobular and mucinous histological types, lower in medullary 
type (p=0.08) (Fig. 13A). No statistically significant differences were found for RB 
expression among histological grades, tumour size, stage (p=0.1 for all of them) and age at 
diagnosis (p=0.7). RB was significantly higher in LN- tumours (p=0.01) and in patients 
who did not develop later recurrences (p=0.01) (Fig. 13B-C).  
CDK2 expression was higher in ductal and lower in tubular carcinomas (p=0.02) (Fig. 
14A). CDK2 expression level was higher in: less differentiated tumour grade (p=0.04) 
(Fig. 14B), tumour size larger than 5 cm (p=0.05) (Fig 14C), LN+ patients (p<0.001) (Fig. 
14D), stage III tumours (p<0.001) (Fig. 14E), and patients who underwent later 
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recurrences (p=0.02) (Fig. 14F). No significant differences were found for CDK2 
expression and the number of involved nodes (cut-off 3 lymph node) (p=0.7), as well age 
at diagnosis, dichotomized at 35 years (p=0.6).  
 
 
  
Fig. 13. Box plot representing significant RB expression ratio stratifying patients according to 
histological type of tumour (A), lymph node involvement (B), presence of later recurrence (C). 
The median value is indicated as a black line in each group. 
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Fig. 14. Box plot representing significant CDK2 expression ratio stratifying patients according to 
histological type of tumour (A), histological tumour grade (B), tumour size (C), lymph node 
involvement (D), tumour stage (E), presence of later recurrence (F). The median value is 
indicated as a black line in each group. 
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4.7.2 HER-2, PI3K, AKTs and RAF1 
HER-2 was more expressed in: ductal carcinomas (p=0.003) (Fig. 15A), tumour with 
lymph node involvement (p<0.001) (Fig. 15B), stage III BC (p<0.001) (Fig. 15C). 
Conversely, no significant differences were observed for histological grade (p=0.4), size of 
tumour (p=0.9), number of positive nodes (p=0.1), presence of later recurrences (p=0.3) 
and age at diagnosis (35 years cut-off) (p=0.6). 
PI3K was similarly expressed among the histological classes of tumour (p=0.2). 
Conversely, PI3K higher expression was detected in tumour characterized by: lower 
histological grade (p<0.001) (Fig. 16A), smaller tumour size (p=0.004) (Fig.16B), no 
lymph node involvement (p<0.001) (Fig. 16C), stage I (p<0.001) (Fig. 16D), absence of 
later recurrences (p<0.001) (Fig. 16 E), patients older than 35 years at diagnosis (p<0.001) 
(Fig. 16F).  
AKT1 was highly expressed in less differentiated tumour (p=0.05) (Fig. 17A), lymph node 
positive (p<0.001) (Fig. 17B), stage II and III (p<0.001) (Fig 17C), in patients who 
developed later recurrences (p=0.02) (Fig. 17D). No significant differences for AKT1 
expression among histological types (p=0.2), tumour size (p=0.7), number of positive 
nodes (p=0.7) and age at diagnosis (p=0.3) were detected. 
AKT2 resulted higher in tumours with grade I (p=0.002) (Fig. 18A), LN- (p<0.001) (Fig. 
18B), stage I (p=0.003) (Fig. 18C), without recurrences (p=0.01) (Fig. 18D), in patients 
with more than 35 years old at diagnosis (p=0.02) (Fig. 18E). Otherwise, no different 
expression was recorded for histological type  (p=0.9) and tumour size (p=0.6). 
AKT3 expression showed significant differences among histological types, with medullary 
and mucinous tumours presented the highest expression level (p=0.002) (Fig. 19A). 
Moreover, higher AKT3 expression was detected in case of grade 1 (p<0.001) (Fig. 19B), 
in smaller tumours (p=0.003) (Fig. 19C), in LN- cases (p<0.001) (Fig 19D), in cancer of 
stage I (p<0.001) (Fig 19E), in patients who did not develop later recurrences (p<0.001) 
(Fig 19F). AKT3 expression did not vary with age at diagnosis (p=0.4). 
RAF1 expression was slightly increased only in LN+ tumours (p=0.06) (Fig. 20). No 
significant differences in its expression were detected for the other variables: histological 
type (p=0.3), grade, tumour size, number of positive nodes, stage (p=0.7 for all of them), 
presence of recurrence (p=0.4), age at diagnosis (p=0.8). 
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Fig. 15. Box plot representing significant HER-2 expression ratio stratifying patients according to 
histological type of tumour (A), lymph node involvement (B), tumour stage (C). The median 
value is indicated as a black line in each group. 
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Fig. 16. Box plot representing significant PI3K expression ratio stratifying patients according to 
histological tumour grade (A), tumour size (B), lymph node involvement (C), tumour stage 
(D), presence of later recurrence (E), age at diagnosis, (F). The median value is indicated as a 
black line in each group. 
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Fig. 17. Box plot representing significant AKT1 expression ratio stratifying patients according to 
histological tumour grade (A), lymph node involvement (B), tumour stage (C), presence of 
later recurrence (D). The median value is indicated as a black line in each group. 
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Fig. 18. Box plot representing significant AKT2 expression ratio stratifying patients according to 
histological tumour grade (A), lymph node involvement (B), tumour stage (C), presence of 
later recurrence (D), age at diagnosis (E). The median value is indicated as a black line in each 
group. 
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Fig. 19. Box plot representing significant AKT3 expression ratio stratifying patients according to 
histological type of tumour (A), histological tumour grade (B), tumour size (C), lymph node 
involvement (D), tumour stage (E), presence of later recurrence (F). The median value is 
indicated as a black line in each group. 
 
 
Fig. 20. Box plot representing significant RAF1 expression ratio stratifying patients according to 
lymph node involvement. The median value is indicated as a black line in each group. 
4.7.3 CK8 
Higher CK8 expression was observed in: mucinous tumours (p=0.04) (Fig. 21A), 
intermediate size tumours (p=0.01) (Fig 21B), LN+ patients (p<0.001) (Fig 21C), stage III 
tumours (p<0.001) (Fig. 21D). Conversely, CK8 expression did not discriminate over 
tumour grade (p=0.1), number of positive nodes (p=0.3), presence or absence of 
recurrence (p=0.3) and age at diagnosis (p=0.5). 
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Fig. 21.  Box plot representing significant CK8 expression ratio stratifying patients according to 
histological type of tumour (A), tumour size (B), lymph node involvement (C), tumour stage 
(D). The median value is indicated as a black line in each group. 
 
4.8 Gene Expression in Molecular Classes 
Subdividing patients into the 4 molecular classes we observed a significant difference in 
the expression levels of: CDK2 (p=0.04) HER-2 (p<0.001), PI3K (p<0.001), AKT2 
(p=0.006), AKT3 (p<0.001) and CK8 (p<0.001) among molecular subtypes. No different 
distribution for RB (p=0.2), AKT1 (p=0.2) and RAF-1 (p=0.3) was observed. The 
corresponding box plot are shown in Fig. 22A-I. A positive correlation was found between 
HER-2 protein by IHC and HER-2 mRNA level (Spearman’s ρ=0.51 and p<0.01). No 
correlation for CK8 expression at the protein and mRNA level was found (ρ=0.3). 
CDK2 was significantly higher expressed in luminal B in comparison to luminal A 
(p=0.006). No significant differences between the other classes were observed. Higher 
mRNA levels of HER-2 were predominantly found in HER-2+ subtype with respect to 
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luminal A, luminal B and basal-like (p=0.0001 for all). In addition HER-2 was more 
expressed in luminal B in comparison to luminal A and basal-like (p=0.0001 for both), but 
also in luminal A in comparison to basal-like (p=0.04). The highest expression level of 
PI3K was recorded in luminal A tumours in comparison with luminal B (p=0.0001), HER-
2 (p=0.0002) and basal-like (p=0.03). Also PI3K expression was observed slightly higher 
in basal-like with respect HER-2 (p=0.06). Carcinomas classified as HER-2+ showed the 
lowest AKT2 expression in comparison to luminal A (p=0.0009), luminal B (p=0.001) and 
basal-like (p=0.02). No differences between luminal A and B (p=0.7), between luminal A 
and basal-like (p=0.3), neither between luminal B and basal-like (p=0.5) was found. AKT3 
was higher in luminal A with respect to luminal B (p=0.001) and HER-2 (p=0.0002), nor 
with basal-like (p=0.3). Moreover, AKT3 was significant higher in basal-like in 
comparison to luminal B (p=0.04) and HER-2+ (p=0.02). No differences were detected for 
AKT3 expression between luminal B and HER-2+ (p=0.1). The highest CK8 expression 
was detected in luminal B class versus luminal A (p=0.0002), HER-2+ (p=0.0003) and 
basal-like (p=0.0001). Also luminal A expressed higher CK8 in comparison with basal-
like (p=0.0001), but not in comparison to HER-2+ (p=0.1). In fact HER-2+ subtypes 
showed higher CK8 with respect basal-like (p=0.02). 
Dividing patients for lymph node involvement, in LN- group only HER-2 and CK8 were 
still differently distributed among molecular classes (Fig. 23A-B). Namely, HER-2+ and 
luminal B tumours displayed the highest HER-2 and CK8 expression respectively 
(p<0.001 for both).  
In LN+ group three genes were differentially distributed among molecular classes (Fig 24 
A-C). HER-2 was prevalently expressed in HER-2+ subtype (p=0.002). AKT2 was mainly 
expressed in luminal and basal-like tumours in comparison to HER-2+ subtype (p=0.03). 
CK8 was mainly expressed in luminal tumours (p<0.001), but without differences between 
luminal A and B (p=0.3) 
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Fig. 22. Box plot representing significant genes expression among molecular classes in the BC 
patients’ cohort (N=303). RB (A), CDK2 (B), HER-2 (C), PI3K (D), AKT1 (E), AKT2 (F), 
AKT3 (G), CK8 (H), RAF1 (I). The median value is indicated as a black line in each group. 
  
Fig. 23. Box plot representing significant genes expression among molecular classes in the LN- group 
of BC patients’ cohort (N=149). HER-2 (A), CK8 (B). The median value is indicated as a black 
line in each group. 
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Fig. 24. Box plot representing significant genes expression among molecular classes in the LN+ group 
of BC patients’ cohort (N=153). HER-2 (A), AKT2 (B), CK8 (C). The median value is 
indicated as a black line in each group. 
 
4.9 Survival Analysis 
4.9.1 Candidate Genes 
For survival analysis genes’ expression level was dichotomized in low expression and high 
expression with respect to the median value of ratio of each gene, in the entire case study.  
The log-rank test revealed that 2 out nine genes affected significantly BC specific survival 
in the cohort of our patients: AKT1 (p=0.04) and AKT2 (p=0.04) (Fig 25 A-B). In detail 
78% of patients with high AKT1 expression level died specifically of BC. A less marked 
difference was detected for AKT2 expression, 56% of patients with high AKT2 status died 
from BC versus 44% having a low one. 
The expression of the other genes was not significant: RB (p=0. 2), CDK2 (p=0.5), HER-2 
(p=0.3), PI3K (p=0.3), AKT3 (p=0.1), RAF-1 (p=0.7), CK8 (p=0.5). 
When BC patients were stratified over lymph node involvement, we obtained different 
results. In LN- group, RB and AKT3 seemed to have a protective effect on patients’ 
survival (p=0.03 and p=0.01, respectively), since higher expression levels were associated 
to longer survival, as shown in Fig. 26 A-B. Particularly, 64% of patients with a low RB 
expression had a BC specific death, against 36% with a high RB status. Similarly, 67% of 
LN- patients with low AKT3 expression died from BC with respect to 33% of women with 
high AKT3. The other genes were not significantly related to BC patients’ survival (CDK2 
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p=0.4, HER2 p=0.3, PI3K p=0.3, AKT1 p=0.4, AKT2 p=0.4, RAF1 p=0.4 and CK8 
p=0.09). 
In LN+ group none of the analysed gene showed influence on BC specific patients’ 
survival (RB p=0.8, CDK2 p=0.6, HER2 p=0.6, PI3K p=0.4, AKT1 AKT2, AKT3 and 
RAF1 p=0.9). 
To confirm the results obtained in the Log-rank survival analysis, Cox proportional hazard 
model was performed using as covariates the pathological variables (histological type, 
histological grade, tumour size, lymph node involvement, age at diagnosis) and the genes 
that resulted statistically significant in the Log-rank test. When the entire cohort of BC was 
analysed, the histological type of tumour (p=0.06), the lymph node involvement (p<0.001) 
and histological grade (p=0.008) affected significantly BC specific survival, but not 
tumour size (p=0.7), age at diagnosis (p=0.5), AKT1 (p=0.2) and AKT2 (p=0.8) 
(probability of the model p=0.000) (Table 16 Part I). Considering solely LN- group, the 
Cox regression model for the abovementioned pathological variables (with the exception 
of lymph node) and for RB and AKT3 genes revealed that histological grade (p=0.03) and 
marginally RB (p=0.08) affected BC outcome (probability of the model p=0.04) (Table 16 
Part II). 
  
Fig. 25. Kaplan-Meyer survival curves for AKT1 expression (A) and AKT2 expression (B) in the 
entire cohort (N=305, 128 BC specific deaths). Gene expression was dichotomized in low 
expression and high expression with respect to the median value of each gene. 
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Fig. 26. Kaplan-Meyer survival curves for RB expression (A) and AKT3 expression (B) in the LN- 
group of patients (N=151, 39 BC specific deaths). Gene expression was dichotomized in low 
expression and high expression with respect to the median value gene. 
Risk Factors Hazard Ratio 95% CI* p 
Age at diagnosis 1.0 0.9-1.0 0.4 
Histological type 0.8 0.6-1.0 0.06 
Grade 1.5 1.1-2.0 0.008 
Tumour size 1.1 0.8-1.5 0.7 
Lymph node 2.6 1.5-4.4 0.000 
AKT1 0.7 0.4 0.2 
AKT2 1.1 0.7-1.6 0.8 
Part I 
  
0.
00
0.
25
0.
50
0.
75
1.
00
Su
rv
iva
l p
ro
ba
bil
ity
0 5 10 15 20 25
Follow−up (years)
Low RB High RB
(p=0.03)
Survival by RB
0.
00
0.
25
0.
50
0.
75
1.
00
Su
rv
iva
l p
ro
ba
bil
ity
0 5 10 15 20 25
Follow−up (years)
Low AKT3 High AKT3
(p=0.01)
Survival by AKT3
A B 
  Results 
87 
 
 
Risk Factors Hazard Ratio 95% CI* p 
Age at diagnosis 1.0 0.9-1.1 0.8 
Histological type 0.9 0.6-1.2 0.4 
Grade 1.7 1.0-2.7 0.03 
Tumour size 1.3 0.6-2.4 0.5 
RB 0.6 0.3-1.1 0.08 
AKT3 0.6 0.3-1.2 0.1 
Part II 
Table 16. Results of Cox proportional hazard model of BC specific survival for Part I: entire cohort 
(N=305, 128 BC specific deaths); Part II: lymph node negative group (N=151, 39 BC specific 
deaths). (*Confidence Interval, p= level of significance for association). 
 
4.9.2 Candidate Genes and Molecular Classification 
The role of the genes as candidate prognostic markers for BC specific survival was 
investigated among the 4 molecular classes taken one a time. A better patients’ survival 
was found for higher level of CDK2 in basal-like tumours (p=0.06) (Fig. 27), lower level 
of AKT2 in luminal B (p=0.03) (Fig 28), and higher level of AKT3 in luminal A tumours 
(p=0.001) (Fig. 29A). In detail, 63% of women classified as basal-like with low CDK2 
expression level died from BC; 78% of luminal B patients with higher AKT2 had a BC 
specific death; 66% of women with low AKT3 died from BC among luminal A patients. 
Dividing patients for lymph node involvement, CDK2 was no more significantly related to 
patient’s survival (p=0.2 for both LN- and LN+). AKT2 also lost its prognostic role when 
it was analysed only in LN- and LN+ group (p=0.2 and p=0.6 respectively). AKT3 
influence on BC survival were confirmed both in LN- and LN+ subgroups of luminal A 
patients (Fig 29B-C). A better overall survival was displayed in patients with high AKT3 
status (LN- p=0.005 and LN+ p=0.04). 73% and 60% of luminal A patients with low 
AKT3 in LN- and LN+, respectively, died of BC.  
Cox proportional hazard regression was performed for CDK2 status and the clinical-
pathological variables in basal-like tumours, but the model was not significant (p=0.09). 
For luminal B tumours the regression was run using as covariates the clinical-pathological 
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data and AKT2 status, in Cox model (p=0.02) only lymph node involvement affected 
marginally (p=0.06) survival, but not AKT2. 
The protective role of high AKT3 status in luminal A tumours was confirmed by Cox 
proportional hazard regression (p=0.000), as shown in Table 17. Lymph node involvement 
(p=0.008), tumour size (p=0.004) and histological grade (p=0.02) conferred an increased 
risk of BC specific death among luminal A patients. 
 
Fig. 27. Kaplan-Meyer survival curves for CDK2 expression over basal-like tumours (N=36, 19 BC 
specific deaths). Gene expression was dichotomized in low expression and high expression 
with respect to the median value of CDK2 gene expression. 
 
Fig. 28. Kaplan-Meyer survival curves for AKT2 expression over luminal B tumours (N=142, 48 BC 
specific deaths). Gene expression was dichotomized in low expression and high expression 
with respect to the median value of AKT2 gene expression. 
  
0.
00
0.
25
0.
50
0.
75
1.
00
Su
rv
iva
l p
ro
ba
bil
ity
0 5 10 15 20 25
Follow−up (years)
CDK2 low CDK2 high
(p=0.06)
Survival by CDK2
0.
00
0.
25
0.
50
0.
75
1.
00
Su
rv
iva
l p
ro
ba
bil
ity
0 5 10 15 20 25
Follow−up (years)
AKT2 low AKT2 high
(p=0.03)
Survival by AKT2
  Results 
89 
 
 
  
Fig. 29. Kaplan-Meyer survival curves for AKT3 expression: (A) over entire luminal A tumours (A) 
(N=140, 45 BC specific deaths); (B) over LN- luminal A tumours (N=98, 22 BC specific death); 
(C) over LN+ luminal A tumours (N=42, 23 BC specific death). Gene expression was 
dichotomized in low expression and high expression with respect to the median value of AKT2 
gene expression. 
 
Risk Factors Hazard Ratio 95% CI* p 
Age at diagnosis 1.1 0.9-1.1 0.1 
Histologic type 0.8 0.4-1.4 0.3 
Grade 1.8 1.1-2.9 0.02 
Tumour size 2.0 1.3-3.3 0.004 
Lymph node 2.3 1.3-4.4 0.008 
AKT3 0.4 0.1-0.8 0.01 
Table 17. Results of Cox proportional hazard model of BC specific survival over luminal A patients 
(N=140, 45 BC specific deaths) (*Confidence Interval, p= level of significance for 
association). 
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4.10 AKTs Expression in Cells Lines 
The mRNA expression of AKTs in cells revealed a slight higher AKT1 expression in 
MCF-7 cells (Ratio 3.49) with respect to SKBR-3 and MDA MB-231 (Ratio 0.58 and 0.59 
respectively, even if not significant (p=0.2). AKT2 expression was similar among the three 
cell lines (Ratio 0.85, 0.96, 1.22 for MCF-7, SKBR-3 and MDA MB 231) (p=0.6). AKT3 
expression was higher in SKBR-3 (Ratio 5.28) and MDA MB-231 (Ratio 4.10) with 
respect MCF-7 (Ratio 0.05), but differences were not significant (p=0.1). The histogram 
representing gene expression of the three AKT isoforms among BC cell lines is reported in 
Fig. 30. 
 
Fig. 30. Gene expression reported as Ct (cycle threshold) of AKT1, AKT2, AKT3 and housekeeping 
gene β-Actin (ACTB) in the three BC cell lines MCF-7, SKBR-3 and MDA MB 231. 
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5 DISCUSSION 
To date, most of the information on patient’s prognosis is based on the combination of 
pathology and immunohistology, which are closely connected to clinical data. However, 
patients who present similar clinically and pathologically tumours can show very different 
clinical outcome with respect to survival and response to therapy. Actually, tumour 
morphology is not able to reflect completely and explain the different alterations in tumour 
cells (Andre and Pusztai, 2006; Dietel and Sers, 2006). In recent years, many efforts have 
been made to deepen understanding the molecular alterations distinctive of each tumour. In 
this context the molecular biomarkers represent the connection between molecular biology 
and clinical diagnosis/prognostication. 
This thesis aims to investigate on the possibility of combining classical pathological features 
with new candidate biomarkers for the prognostication of breast cancer. This target was 
pursued by performing molecular analyses on formalin fixed paraffin embedded tissues 
specimens in order to directly compare experimental results with the clinical data and 
follow up. 
 
5.1 Prognostic Role of Clinical and Pathological Features 
Treatment decisions after surgery for BC patients are still based largely on clinical and 
pathological parameters. These parameters include: age at diagnosis, histological type of 
tumour, tumour grade, tumour size, lymph node involvement and presence of later 
recurrences (Colombo et al., 2011; Rakha and Ellis, 2011; Soerjomataram et al., 2008). 
Their prognostic values were assessed in a cohort of 305 BC young patients, age at 
diagnosis ≤ 55 years, characterized by a long follow-up. 
As a first point, we separated patients according to lymph node involvement and compared 
the clinical pathological parameters between these two groups. It emerged that patients with 
age at diagnosis ≤ 35 years were more frequent in the LN+ group, according to the fact that 
very young women exhibited a more aggressive disease and poor survival (Kroman et al., 
2000; Soerjomataram et al., 2008). Moreover, some histological types of tumours were 
significantly associated to the lymph node involvement. For instance, we observed that 
medullary and tubular tumours belonged mostly to LN- group, according to Ellis et al. who 
  Discussion 
92 
 
reported that axillary node metastases do not occur frequently in tubular tumours and are 
detected only in less than 10% of medullary carcinomas (Ellis et al., 2003). Otherwise, 
ductal tumours represented the vast majority of LN+ patients. Another variable that resulted 
strictly associated to the lymph nodes status was the tumour grade. Most low-grade tumours 
were LN- (G1 rate: 22% in LN- and 3% in LN+), while high-grade tumours were found in 
LN+ group (G3 rate: 21% and 59% in LN- and LN+ respectively), as previously reported 
(Galea et al., 1992; Rakha et al., 2008a; Rakha and Ellis, 2011). Tumour size, an important 
BC prognostic factor, was directly related to the presence of nodal metastasis, as previously 
reported (Edge et al., 2010a; Rakha and Ellis, 2011). Furthermore, from our analysis it 
resulted that tumour larger than 5 cm were mainly in LN+ group, while almost three quarter 
of lymph node negative patients showed tumours less than 2 cm in size. We also found that 
only one third of LN- patients developed later recurrences, while more than two third of 
LN+ women recurred, in agreement with Rakha et al. (Rakha et al., 2010). 
As expected, the Log-rank test revealed a strong association between those clinical-
pathological features and patients’ outcome, as already reported by several authors (Elston 
and Ellis, 1991; Rakha et al., 2010; Soerjomataram et al., 2008; Weigelt et al., 2010b). 
Histological type of tumour (p=0.004), tumour grade (p<0.001), tumour size (p=0.02), 
lymph node involvement (p<0.001), number of positive nodes (p=0.01) and presence of 
recurrences (p<0.001) affected significantly BC specific survival in our cohort of patients. 
We did not find a significant influence of age at diagnosis on BC specific survival. 
Nevertheless, multivariate Cox regression analysis confirmed an independent influence on 
BC specific survival for histological type of tumour (p=0.04), tumour grade (p=0.006) and 
lymph node status (p<0.001). In particular, the histological type of BC showed a protective 
role on patient’s survival, while positive lymph node involvement and tumour grade were 
poor prognostic factors. Similar independent prognostic value was recorded for tumour 
differentiation and lymph node involvement, in agreement with Rakha et al. who reported 
that in early BC stages the histological grade had a prognostic value equivalent to that of LN 
status, even higher than tumour size (Rakha et al., 2008a). Therefore, we strongly believe 
that beyond lymph node status, tumour grade is highly crucial for prognostication especially 
for those tumours with same stage at diagnosis. 
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5.2 Prognostic Role of Molecular Classification 
Gene expression profiling through microarray technology has led to the establishment of a 
molecular taxonomy as a tool for supporting the clinical management of patients (Colombo 
et al., 2011; Perou et al., 2000; Sorlie et al., 2001; Sotiriou and Pusztai, 2009). Accordingly, 
breast tumours can be grouped into at least four “intrinsic” molecular subtypes: two 
luminal-like ER-positive subtypes, and two ER-negative subtypes, the HER-2 
overexpressing and the basal-like subtypes, which is also defined triple negative (TN) 
because of negativity to ER, PR and HER2 (Valentin et al., 2012). However, given to the 
limit of microarray-based molecular classification in clinical practice, 
immunohistochemical-based classification using the molecular markers ER, PR, HER2, and 
Ki67 (with a cut-off of 14%) has been proposed as a surrogate of the molecular 
classification (Goldhirsch et al., 2011; Gruver et al., 2011; Guiu et al., 2012; Muller et al., 
2011; Park et al., 2012; Tang et al., 2009; van de Rijn et al., 2002). Nonetheless, molecular 
classification remains a working model, since a consensus on the definition of molecular 
classes and on standardization of methodologies has not yet been reached (Geyer et al., 
2012; Rakha and Ellis, 2011; Tang et al., 2009). 
In this study, to molecularly classify the tumours we used a panel of six biomarkers in IHC 
assay: ER, PR, HER-2, Ki67, CK8, CK5/6 (Gruver et al., 2011). In addition vimentin 
expression was analysed in all tumour sample, because it has been recognized as marker for 
epithelial-to-mesenchymal transition (Satelli and Li, 2011). The distribution of the 
molecular classes among our cohort of patients was similar to others studies (Dawood et al., 
2011; Park et al., 2012; Weigelt et al., 2010a; Wiechmann et al., 2009): luminal tumours 
representing the majority of cases with 80% (46% and 34% luminal A and luminal B 
respectively), followed by basal-like (12%) and HER-2+ subtype (8%).  
 
Similarly to other studies we observed significant association between the clinical-
pathological features and the molecular subtypes (Gruver et al., 2011; Sorlie et al., 2001; 
Tang et al., 2009; Weigelt et al., 2010b). In detail, most of low-grade tumours displayed 
features of luminal A, conversely high-grade were mainly luminal B, HER-2 and basal-like 
subtypes, in agreement with previous results (Livasy et al., 2006; Tang et al., 2009; Weigelt 
et al., 2010a). Regarding BC histology, tubular and mucinous carcinomas, which are 
associated with a favourable prognosis (Ellis et al., 2003), were mostly luminal tumours, as 
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well as lobular. Conversely, the more aggressive HER-2 subtype and basal-like were mostly 
ductal, as already reported (Garcia Fernandez et al., 2012; Valentin et al., 2012). We 
observed that most of the medullary tumours belonged to the basal-like group, in agreement 
with previous reports (Soerjomataram et al., 2008; Valentin et al., 2012; Weigelt et al., 
2010b). Patients younger than 35 years at diagnosis, often associated to more aggressive 
tumours (Soerjomataram et al., 2008), belong principally to luminal B and HER-2+ 
subtypes. 
The distribution of molecular subtypes between the LN- and LN+ groups revealed 
significant differences (p<0.001). In particular, luminal A type was mainly observed in LN-, 
while luminal B was the most frequent type in the LN+ group. Luminal B and HER-2+ 
tumours were significantly associated to positive lymph nodes in comparison to luminal A 
and HER-2, in agreement with previous result (Wiechmann et al., 2009). Luminal B type, 
indeed, displays an intermediate rate of positive loco-regional lymph nodes between luminal 
A and HER-2+ (Wiechmann et al., 2009). Conversely, basal-like were equally distributed 
between LN- and LN+ groups. Some recent studies reported that the basal-like, despite its 
poor prognosis, was associated to a lower incidence of positive lymph node involvement 
(Crabb et al., 2008; Foulkes et al., 2004), indicating that its intrinsic aggressive behaviour is 
partially independent from the clinical stage.  
No significant differences for size of tumour among molecular classes were found, in 
disagreement with other studies, which showed an association between TN subtype and 
larger tumour size (Garcia Fernandez et al., 2012; Park et al., 2012; Wiechmann et al., 
2009). However, the overall clinical stage well explained the different aggressiveness of 
molecular classes. Notably, luminal A tumours were mainly of stage I, luminal B of stage II, 
and HER-2 tumours of stage III. Basal-like type represents a distinct group of tumours, 
which exhibited heterogeneous biological behaviour that can not be thoroughly explained 
by means of traditional clinical-pathological features (Rakha et al., 2008b). 
Regarding relapses, we observed that more than half luminal A tumours did not exhibited 
recurrences, while HER-2+ tumours presented the highest percentage of recurrences, as 
already reported by Park et al. (Park et al., 2012). Luminal B and basal-like showed a 
similar frequency of recurrences. Nonetheless, luminal A and B exhibited comparable 
frequencies of recurrences if matched by lymph node involvement: in LN- cases luminal A 
showed 32% and luminal B 27% of recurrences, in LN+ 65% and 66% respectively. This 
data were also supported by BC specific survival. This result reflects the fact that luminal A 
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and B cancers differ only for the rate of Ki67 and HER-2 overexpression, both characteristic 
of higher aggressiveness. In comparison to luminal A, Luminal B tumours were often 
negative to PR (p=0.03), but positive to vimentin (p=0.003), both characteristics seem to be 
associated to worse outcome. In agreement, it was previously reported that patients with 
high levels of PR within their tumour have a better outcome than low expressors, in patients 
treated with tamoxifen (Weigel and Dowsett, 2010). Recent studies have reported that 
vimentin plays a major role in the EMT process of BC, and its knockdown resulted in a 
decrease in genes linked with BC invasion. Indeed, vimentin expression was prevalently 
found in high-grade ductal carcinomas (Satelli and Li, 2011). 
About the metastatic sites, we observed that basal-like as well as HER2+ subtypes presented 
higher rate of brain metastasis in comparison to luminal A tumours, in agreement with other 
reports (Crabb et al., 2008; Rakha et al., 2008b). Conversely, HER2+ tumours were not 
prone to develop bone metastases. 
 
To our knowledge we are the first to investigate the BC specific survival associated to 
molecular classes in a population with up to 25-years of follow-up. As expected, we 
observed that BC specific survival analysis identified two well separate groups of tumours: 
the ER-positive and ER-negative. Luminal A had the best outcome, luminal B showed an 
intermediate overall survival, while basal-like and HER-2 types showed the shortest 
survival (p<0.001), as already reported (Garcia Fernandez et al., 2012; Geyer et al., 2012; 
Park et al., 2012; Perou et al., 2000; Sorlie et al., 2001). Patients of this study were enrolled 
before the availability of trastuzumab and, as expected, HER2+ cancers exhibited the worst 
survival.  
The longer survival for both luminal A and luminal B tumours was also confirmed by Cox 
proportional hazard model. Taken together our results, we stress that luminal A and luminal 
B belong to the same group of tumours, their clinical and pathological differences are 
mainly related to different tumour stage at diagnosis. This is also confirmed by the fact that 
for luminal tumours the most important predictor of prognosis remained the lymph node 
involvement and the histological grade.  
Although luminal, or better ER+ tumours are usually referred as less aggressive, they 
undergo frequently over 10 year long-term recurrences (Park et al., 2012). It is important to 
underline that referring to the period of diagnosis of our patient’s cohort (1983-1993), LN- 
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patients were not treated with cytotoxic chemotherapy, according to regimens of those 
years. As a consequence, we observed the real biological history of LN- luminal B tumours. 
In our case study 10% of patients having luminal tumours died from BC even after 10 year 
of follow-up. It is possible to hypothesize that those patients characterized by high mitotic 
index, lymph node negative, vimentin positive, small tumour size and lower grade harbour 
some specific biological properties that slow down progression of carcinoma and may 
postpone the BC specific death even after 20 years. This finding could be possibly 
explained by the dormancy of cancer cells. It is believed that dormant tumour cells are 
resistant to adjuvant therapies and are responsible for recurrences and cancer death with 
mechanisms of transition from latency to proliferative status that are, to date, largely 
unknown (Paez et al., 2012). In the recent St. Gallen guidelines it is reported that adjuvant 
chemotherapy for women with luminal B tumours should be recommended, while it could 
be skipped in luminal A (Goldhirsch et al., 2011). We partially disagree with this indication 
because we observed that, even if at lower rate, also luminal A patients presented long-term 
recurrences. Therefore, we strongly believe that monitoring and follow-up program could be 
different for subtype of cancers and, in case of luminal tumours prolonged controls are 
recommended because of the possibilities of later relapses.  
To conclude, we think that the use of the traditional biomarkers (ER, PR, HER-2) is 
essential for BC characterisation and prognostication in association with clinical 
pathological features. Molecular classification represent a mere reflection of hormone 
status, HER-2 and proliferation status, as already reported (Rakha and Ellis, 2011). 
Moreover, we stress that luminal A and B represents the same group of tumours, but 
observed at different time of progression. Additionally, we believe on the usefulness of 10% 
cut-off for Ki67 in substitution of 14% threshold (Cheang et al., 2009) to discriminate 
between luminal tumours. To support our opinion, also the IMPAKT 2012 working group 
judged as inadequate the clinical utility of the 14% cut-off for discriminating luminal A 
/luminal B tumours as a basis to decide the use of adjuvant chemotherapy (Guiu et al., 
2012).  
 
5.3 Prognostic Role of Markers in Metastatic Lymph Nodes 
Many clinical and pathological factors, as tumour grade, age at diagnosis (Hayes, 2005; 
Patani et al., 2007), tumour size, as well as hormone receptor status and HER-2 
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amplification status (Cavalli, 2009) were associated to lymph node metastasis, as shown in 
this study. However, many of the abovementioned features failed in predicting the 
development of later recurrences (Cavalli, 2009; Zhou et al., 2012).  
To understand the molecular alteration connected to the metastatic progression, we 
compared the phenotype of primary tumour cells with their corresponding metastatic cells 
colonizing loco-regional nodes. By comparing the expression of markers ER, PR, HER-2, 
Ki67, CK8, CK5/6 and vimentin by IHC, we found that HER-2, Ki67, CK8 and vimentin 
positivity was frequently lost at the lymph node level, but an increment of CK5/6 positivity 
was observed in the metastatic site. The lower mitotic proliferation index found in the 
metastatic lesion could be explained by the adverse microenviroment of the lymph node for 
the replication of cancer cell. In contrast with our result, Park et al. reported an increased 
Ki67 positivity in metastatic lesion compared to the primary tumour (Park et al., 2007). This 
discrepancy it could be related to different cut-off level for positivity and different methods 
of analysis. In our study, indeed, we performed microdissection through TMA technique to 
isolate and analyse tumour areas from the lymph node, while Park et al. processed the entire 
slide. Positivity to ER and PR was similar in primary and matched metastatic tumours in our 
cohort, in agreement with a previous work (Tawfik et al., 2013). However, on average the 
number of positive nuclei for both ER and PR was higher in the metastatic counterpart: the 
mean of ER nuclei was 54% and 65% in primary and metastatic lesion, respectively; for PR 
it was 40% and 53% respectively. 
The expression of the markers was combined in order to classify molecularly both primary 
tumour and the corresponding metastatic lesion. Molecular classification was partially 
maintained during the process of metastatization, although the expression of CK8 and 
CK5/6 significantly changed. We could hypothesize that only some cells of the primary 
tumours are able to colonise lymph nodes, and those cells could likely be characterised by 
the basal/myoepithelial phenotype (CK5/6+), which represents the proliferating counterpart 
of breast epithelia(Iyer et al., 2013; Moll et al., 1982). 
In order to investigate the prognostication of the analysed markers at the lymph node level, 
we studied BC specific patients’ survival separately in primary and metastatic sites. 
Surprisingly, CK8 expression assessed in lymph node metastatic specimens resulted to be a 
marker of good prognosis. The number of analysed specimens allows reaching a power of 
the study of 0.9985, supporting the strength of this finding. This result was also confirmed 
by Cox’ multivariate hazard regression model (p<0.001). To our knowledge, this is the first 
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study showing that positivity to CK8 in metastatic lymph nodes is significantly associated to 
longer patients’ survival. Although this is a preliminary result, which should be confirmed 
in a larger cohort of patients, we believe that the assessment of CK8 in regional metastatic 
lymph nodes by means of IHC is feasible and reliable in clinical diagnostic.  
 
5.4 Prognostic Role of Candidate Genes 
Most candidate genes analysed in this study resulted associated with clinical and 
pathological features, except RAF1. In detail, AKT3 expression was significantly associated 
to lobular, mucinous and tubular carcinomas, which presented a usually good prognosis 
(Ellis et al., 2003). HER-2, CDK2 and CK8 were significantly more expressed in ductal 
tumours, often associated to a worse outcome (Ellis et al., 2003). PI3K, AKT2 and AKT3 
expression was significantly associated to low-grade tumours, while CDK2 and AKT1 to 
high-grade cancers. Regarding tumour size, PI3K and AKT3 expression was significantly 
related to small cancers, whereas CDK2 and CK8 expression to larger ones. 
Regarding the relationship between genes expression and lymph node involvement, 
significant differences between LN- and LN+ groups was found for all the genes, except 
RAF1. A higher expression of RB, PI3K, AKT2 and AKT3 was detected in LN- group, 
even in patients without later recurrences. On the contrary, higher expression of CDK2, 
HER-2, AKT1 and CK8 in LN+ group was found. Data on CK8 were supported from 
Brotherick et al., who detected higher CK8 mRNA levels in node positive in comparison to 
node negative patients (Brotherick et al., 1998). CDK2 high expression was significantly 
associated to the presence of later recurrences in the entire cohort, in agreement with others 
authors (Bonin et al., 2008; Kim et al., 2008).  
Accordingly, we hypothesise that a high mRNA status for RB, PI3K, AKT2 and AKT3 are 
associated to favourable clinical and pathological features in BC patients. In addition, 
expression levels of AKT3 and PI3K were significantly higher in living patients in 
comparison to those dead of breast cancer. The favourable prognostic role of PI3K agrees 
with recent reports (Dawson et al., 2013; Kalinsky et al., 2009), although in the present 
study we did not analyse the mutational status of PI3K. On the other hand, the expression 
levels of CDK2, HER-2, AKT1 and CK8 associated to unfavourable clinical and 
pathological features. HER-2, AKT1 and CK8 expression levels were significantly higher in 
patients who died from breast cancer, compared to living patients.  
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Stratifying patients into the 4 molecular classes, significant associations were found for 6 
out of the 9 genes: CDK2, HER-2, PI3K, AKT2, AKT3 and CK8. Lower expression level of 
CDK2 was detected in luminal A. HER-2 was mainly expressed in HER-2+ subtype, as 
expected. PI3K expression as well as AKT3 was higher in luminal A tumours in comparison 
with the others subtypes. Higher AKT2 level was mainly found in luminal and basal-like 
subtypes and the expression of CK8 was mostly found in luminal B.  
 
The survival analysis for gene’s expression in the entire cohort of patients, revealed that 
high status of AKT1 and AKT2 expression was significantly associated to worse outcome, 
although AKT2 was previously associated to favourable clinical BC factors. 
When we analysed survival only in the LN- group, we observed that high RB, as previously 
reported (Bosco and Knudsen, 2007; Musgrove and Sutherland, 2010) and high AKT3 were 
significantly associated to longer BC specific survival. Any gene did not result significant 
for BC specific survival in the LN+ group. 
Low expression of AKT2 in luminal B and high AKT3 expression in luminal A were 
significantly associated to longer patients’ survival. Data on AKT3 agree with a previous 
study conducted in our laboratory, which was performed using a different assay, namely the 
quantitative end point PCR with different primers, and also in a different case study, 
composed of young and old women (Bonin et al., 2008).  
In the present study AKT3 seems to be an independent indicator of good prognosis in 
luminal A tumours. To our knowledge, only few studies reported on the role of isoform-3 of 
the AKT gene, especially in BC. In agreement with us, a previous study performed on lung 
cancers showed that high AKT3 and PI3K protein levels in the stroma were independent 
positive prognosticators for patients’ survival suggesting a paracrine effect of AKT on the 
tumour cells (Al-Saad et al., 2009). Nevertheless, we believe that the high AKT3 mRNA we 
detected could be related to cancer cells rather than stroma, because of the accurate 
microdissection performed in this study to avoid lymphocytes and stroma contamination. In 
disagreement with our findings, Grabinski et al. proved in lung cancers cells the 
contribution of AKT3 to proliferation, survival and migration of tumour cells (Grabinski et 
al., 2011). These discordant results may be due to the different techniques used, 
immunohistochemistry vs western blot, but also to the sample used for the analysis, FFPE 
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and cell lines respectively. To confirm this hypothesis we detected different pattern of 
AKTs expression in FFPE tissues and cell lines, representative of BC molecular classes. 
To our knowledge, our study is the first one that investigated the expression of AKT 
isoforms in a large cohort of human breast cancer samples. AKT1 and AKT2 high 
expression seem to be associated to worse BC patient’s prognosis, in term of higher risk to 
develop later recurrences (AKT1) and shorter BC survival (AKT1 and AKT2), in agreement 
with previous results of cell biology (Chin and Toker, 2009; Toker, 2011; Wickenden and 
Watson, 2010). For AKT3 very few and contrasting results are present in literature. 
Although recently many studies have sought to understand the role of PI3K/AKT pathway 
in breast tumourigenesis, the specific functions and the direct substrates of each AKT 
isoform remain to be identified. It is, indeed, well known that different isoforms of AKT 
could have different functions depending on the type of cells and of tissues. The main 
problem to unravel the function of this regulatory system of proteins is the identification of 
the specific substrates for AKTs, especially AKT3. At the present time more than 200 
substrates have been identified but without specific indication on the distribution among the 
AKTs (Toker, 2011).  
 
OVERVIEW DIAGRAM 
 
Fig. 31. Overview diagram of our suggestion for BC patients’ prognosis.  
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6 CONCLUSIONS 
Traditional morphological approaches are of undeniable importance in breast cancer 
classification. However, they are not sufficient to properly predict the clinical behaviour of 
tumours, because BC is characterized by a wide heterogeneity, also at molecular level. 
These limitations could be overcome by the use of molecular biomarkers in addition to 
pathological classification, aiming to a more personalized approach in the prognostication 
and therapeutic decisions.  
This thesis focused on the research ad validation of new candidate prognostic molecular 
markers in association to the classic pathological features in a cohort of 305 young BC 
patients with long follow-up. 
According to our findings we conclude that: 
• All the clinical-pathological features analysed revealed a significant prognostic role 
on BC specific patient’s survival: histological type of tumour, tumour grade, tumour 
size, lymph node involvement, number of positive nodes, and presence of 
recurrences (p<0.001). 
• The lymph node involvement is the most important clinical and prognostic factor. 
LN- group showed a significant better clinical outcome with respect to LN+. 
• The most important marker to be assessed is ER, because its expression identifies 
two different populations of patients with completely opposed clinical outcome: 
ER+ group showed a better clinical outcome compared to ER- group. 
• In the ER+ group of patients, the positive expression of PR represents a favourable 
prognostic factor, which is associated to longer BC specific survival. Additionally, 
negativity to vimentin is a good prognostic marker in this group. 
• We believe that luminal A and luminal B tumours belong to the same group of ER+ 
tumour: clinical differences of luminal A and B are the result of different tumour 
stage at diagnosis, with luminal B presenting the higher one. 
• Despite of the better prognosis of luminal tumours, ER+ patients could present very 
long-term recurrences, even after 10 years. For this reason we believe that longer 
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monitoring program of follow-up are needed for ER+ patients, even in those cases 
associated to good prognosis. 
• HER-2 is a worse prognostic marker associated to shorter BC survival in ER- group, 
not in ER+. 
• ER- tumours, namely HER-2+ and Basal-like or TN, showed very poor outcome, 
with a BC specific death within 5 and 10 years of follow-up. However we 
acknowledge that HER-2+ patients were not submitted to trastuzumab, which is now 
recommended in cases of HER-2 amplification. Basal-like cancers represent a 
unique aggressive group of tumours with apparent independence from the traditional 
pathological features.  
• CK5/6 and vimentin markers are important to confirm the basal-like subtype, but 
they do not seem to affect BC survival over this group of patients. 
• HER-2+ and basal-like subtypes showed the higher rate of brain metastasis, in 
comparison to the others subtypes. These findings could be important to deepen the 
process of BC metastatization. 
• The assessment of the CK8 expression in the metastatic regional lymph node proved 
to be a novel tool for prognostication of LN+ patients. Positivity to CK8 by IHC in 
lymph node metastatic tissue resulted a favourable indicator of longer BC survival. 
• RB, PI3K, AKT2 and AKT3 were highly expressed in LN-, while CDK2, HER-2, 
AKT1 and CK8 in LN+.  
• CDK2 and AKT1 high expression seem to have an influence on the development of 
later recurrences in our cohort of BC patients.  
• LN- patients with high RB and AKT3 expression seem to have longer survival time. 
• AKT3 expression in ER+ HER-2- and low proliferation index patients was 
associated to longer BC specific survival. 
Although the results produced in this PhD project are encouraging and provide some new 
topic for BC research, further confirmations in larger retrospective and prospective studies 
are needed. 
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